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ABSTRACT
Metabolic Regulation is a complex system used to control cellular metabolism in
response to conditions in the cell’s environment. For most enzymes, the cell can rely upon a
minimal amount of regulation; however, critical enzymes, such as acetyl-CoA carboxylase, must
be regulated at multiple levels. Acetyl-CoA carboxylase catalyzes the first committed step in
fatty acid synthesis. In bacteria, acetyl-CoA carboxylase forms a complex of three subunits–
biotin carboxylase, biotin carboxyl carrier protein, and carboxyltransferase–which catalyze the
carboxylation of acetyl-CoA to form malonyl-CoA via two half-reactions. In the first halfreaction, biotin covalently linked to biotin carboxyl carrier protein is carboxylated by biotin
carboxylase. Carboxyltransferase catalyzes the second half-reaction where the carboxyl group is
transferred from carboxybiotin to acetyl-CoA, forming malonyl-CoA. As acetyl-CoA
carboxylase is a critical enzyme in cell growth, it is subject to multiple forms of regulation. This
dissertation describes two distinct mechanisms of regulation of acetyl-CoA carboxylase.
Previous reports showed that the downstream product of fatty acid synthesis, palmitoyl-acyl
carrier protein, inhibits catalysis by acetyl-CoA carboxylase via negative feedback regulation.
This dissertation reports the acetyl-CoA carboxylase complex was found to exhibit a pronounced
hysteresis when inhibited by palmitoyl-acyl carrier protein. Alternatively, palmitoyl-acyl carrier
protein does not inhibit either half–reaction. Structure-function studies of palmitoyl-acyl carrier
protein demonstrate the inhibitory moiety is the cofactor pantothenic acid. This dissertation also
reports that the biotin carboxyl carrier protein subunit of acetyl-CoA carboxylase regulates
catalysis. The biotin carboxyl carrier protein in E. coli is composed of two domains: the Nterminal domain, and the C-terminal domain. The C-terminal domain contains the biotin
cofactor, and acts as a substrate, while the function of the N-terminal domain was unknown. In
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vivo pull-down assays demonstrated the N-terminal domain is not required for formation of the
catalytic complex, whereas in vitro analyses demonstrated that the N-terminal domain binds
biotin. Thus, it is likely the role of the N-terminal domain of biotin carboxyl carrier protein in
bacterial acetyl-CoA carboxylase is to bind and stabilize the carboxybiotin intermediate during
catalysis.
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CHAPTER 1. INTRODUCTION
1.1 Bacterial Metabolic Regulation
1.1.1 Background
Research into metabolic pathways has roots as early as the 17th century [1]; however, the
modern concept of metabolism first appeared in the mid-19th century when Pasteur began
research into fermentation [2, 3]. The concept of metabolism was further advanced by the
discovery of enzymes by Eduard Buchner in the mid-20th century. The work of both Pasteur and
Buchner laid the groundwork for the revelation that enzymes do not act independently, but
instead are part of a complicated metabolic network [4]. The activity of the enzymes in the
metabolic network are regulated in response to changes in the cellular environment.
In bacteria, there are four main types of regulation to maintain homeostasis in the cell [3].
The first two types of regulation are transcriptional and translational, which are used to control
protein production at the genetic level. The third type of regulation is post translational
modifications (PTMs), which can activate or inactivate an enzyme. The fourth most common
type of metabolic regulation is enzyme-metabolite interactions, i.e. negative or positive feedback
or feed-forward regulation. Examples of each of these types of regulation are given below.
1.1.2 Transcriptional Regulation
The most influential report on transcriptional regulation was the study of the lac operon
in E. coli by Jacob and Monod [5]. Jacob and Monod determined the lac operon is regulated
positively by lactose and negatively by glucose. Glucose is the primary energy source required
for metabolism; however, in the absence of glucose bacterial cells can metabolize lactose for
energy. In order to use lactose, the cell must first transcribe the genes coding for the enzymes
that metabolize lactose, which are encoded on the lac operon. (Figure 1.1, Purple, Yellow, and
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Red). In the absence of lactose, a repressor binds the operator (Figure 1.1, Grey) preventing
RNA polymerase from binding the promoter region (Figure 1.1 labelled), and by inference from
transcribing of the genes. However, when lactose is present an isomer of lactose (allolactose)
binds the repressor to cause a conformational change. The repressor is then forced to release the
operator allowing RNA polymerase to bind and transcribe the genes. Expression of the lac
operon is increased when glucose levels are low. In the absence of glucose, cyclic AMP (cAMP)
concentrations increase allowing cAMP to bind the catabolite activator protein (CAP). This
causes a conformational change in CAP allowing the protein to bind the CAP site (Figure 1.1,
Green). Binding of CAP to the CAP site increases transcription rates for the lac operon [5].
Alternatively, in the presence of glucose, there is a low concentration of cAMP, meaning less
activated CAP to bind the CAP site. Though the lac operon can still be transcribed in the absence
of the activator, it is at a slower rate.

Figure 1.1. Schematic of the lac Operon. The cap binding site (green), the leader region (blue),
and the operator (grey) are labelled. The catalytic enzymes the genes code for are in purple,
yellow and red. The promoter (black) is composed of both the leader region (blue) and part of the
operator (grey).
Similar to the lac operon, the trp operon relies on transcriptional regulation to control the
expression of the genes it encodes. The trp operon contains genes for the proteins required for
tryptophan biosynthesis (Figure 1.2, Navy, Red, Green, Brown, and Pink), and is regulated in
two ways: via a repressor and attenuation [6].
When tryptophan levels are high, tryptophan binds a repressor causing a conformational
change which allows the repressor to bind the operator (Figure 1.2, Light Pink). This blocks
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RNA polymerase from binding (and, therefore, from transcribing) the operon. Alternatively,
when tryptophan levels decrease, tryptophan will release the repressor, causing the repressor to
detach from the operon, allowing the genes to be transcribed. [6].

Figure 1.2. Schematic of the trp Operon. The promoter (blue), the operator (light pink), and the
leader region (purple) are labelled. The enzymes for tryptophan biosynthesis coded for by the
operon are in navy, red, green, brown, and pink, respectively.
The trp operon is also regulated via attenuation. Between the operator and Trp E there is
a leader region (Figure 1.3) containing four sections. The first section (Figure 1.3, Purple) codes
for a 14-amino acid polypeptide containing two tryptophans. Sections 2, 3, and 4 (Figure 1.3
Red, Green, and Pink, respectively) are non-coding regions referred to as attenuator regions. As
RNA polymerase transcribes the genes, a ribosome binds to the transcript, initializing translation.
If there is a surplus of tryptophan in the cell, the ribosome is able to translate the leader
polypeptide (Figure 1.3, Purple). As the ribosome translocates, it covers both regions 1 and 2 of
the mRNA (Figure 1.3 Purple and Red, respectively). This allows attenuator regions 3 and 4
(Figure 1.3, Green and Pink, respectively) of the mRNA to base pair forming a hairpin loop,
which causes RNA polymerase to release the DNA without completing transcription.
Alternatively, if the concentration of tryptophan is low in the cell, then when the ribosome binds
the still-forming transcript it will pause on the two codons for tryptophan in region 1 of the
mRNA (Figure 1.3, Purple). This allows regions 2 and 3 (Figure 1.3 Red and Green,
respectively) of the mRNA to base pair, forming a hairpin loop that prevents region 3 (Figure
1.3, Green) from pairing with region 4 (Figure 1.3, Pink). RNA polymerase will then continue
transcription of the genes for tryptophan biosynthesis [6].
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Figure 1.3. Schematic of the trp Operon and the Leader Sequence. The promoter is blue, the
operator is light pink, the leader region is purple, and the enzymes coded for by the operon are
navy, red, green, brown, and pink, respectively. The leader region is identified and contains four
regions: the leader poly peptide region (1, purple) and three attenuator regions (2 (red), 3 (green),
and 4 (pink)).
Transcriptional control of enzyme production is beneficial, yet this type of regulation
requires time and energy to adjust to changes in the environment. Thus, the cell employs
translational regulation in order to respond more quickly
1.1.3 Translational Regulation
Most translational control is directed towards initiation because it is the rate-limiting step.
One example is the negative regulation threonyl-tRNA synthetase (ThrRS) exhibits by binding
its mRNA [7, 8]. Threonyl-tRNA synthetase is the enzyme in E. coli that charges tRNAThr in an
ATP-dependent manner. When threonine levels are high, ATP and threonine bind ThrRS,
inducing a conformational change that causes the enzyme to preferentially bind tRNAthr [9].
Alternatively, in the absence of threonine ThrRS preferentially binds its mRNA thereby
preventing translation. Figure 1.4 is a representation of the initiation and autoregulatory regions
in the leader region of the mRNA for ThrRS. The leader region of the mRNA for ThrRS is
composed of four domains. Domain 1 consists of one part of the split ribosome binding site, the
Shine Dalgarno sequence (Green), and the methionine start codon (Green). The second part of
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the split ribosome binding site is in domain 3, which also contains a noncoding region of the
mRNA. Domain 2 and domain 4 contain hairpins (Pink) where free ThrRS binds in the absence
of threonine. It is important to note that ThrRS recognizes and binds Domains 2 and 4 (Pink)
because the hairpins mimic the anticodon arm of tRNAthr, (which ThrRS binds when in the
presence of threonine). The bases that are similar to the anticodon of tRNAthr are in blue. The
anticodon arm of tRNAthr is shown in black as a reference, with the corresponding bases also in
blue [10].

Figure 1.4. mNRA for ThrRs in E. coli. The mRNA is organized into four domains. Domain 1
contains part of the split ribosome binding site (labelled), the Shine Dalgarno sequence (green),
and the start codon (green). Domain 3 contains the rest of the ribosomal binding site. Domains 2
and 4 are the hairpins where ThrRS binds. Blue represents the anticodon in the tRNAthr (black)
and the recognition site for ThrRS of the mRNA hairpins (pink). From Babitzke et al [10].
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1.1.4 Post Translational Modifications
The activity of an enzyme can also be controlled via post translational modifications. Post
translational modifications (PTMs) are defined as covalent alterations made to an enzyme that
may change its properties [3]. An example of a PTM in E. coli is the inactivation of isocitrate
dehydrogenase via phosphorylation. This phosphorylation is carried out by the enzyme isocitrate
kinase/phosphatase, an enzyme that catalyzes both the phosphorylation and dephosphorylation of
isocitrate dehydrogenase [11, 12]. Isocitrate dehydrogenase (from the citric acid cycle)
decarboxylates isocitrate to form α-ketoglutarate and carbon dioxide when glucose is available.
Alternatively, when glucose is absent, the cell must use the glyoxylate cycle to bypass the
decarboxylation steps of the TCA cycle to conserve carbons. Thus, in the absence of glucose
isocitrate dehydrogenase is phosphorylated, and therefore inactivated, causing the concentration
of the substrate isocitrate to increase. Isocitrate is then diverted to the glyoxylate cycle, where the
enzyme isocitrate lyase cleaves isocitrate into succinate and glyoxylate. Succinate can then be
incorporated directly into the TCA cycle while glyoxylate must be converted to malate by malate
dehydrogenase before being incorporated into the citric acid cycle.
Like both transcriptional and translational regulation, PTMs are used to maintain
homeostasis. Though PTMs can be enacted faster than transcriptional or translational regulation,
these modifications usually require other enzymes and an energy source, such as ATP, to make
these modification [3]. In contrast, enzymatic activity can also be regulated without the aid of
other enzymes or an energy source by interacting with metabolites.
1.1.5 Enzyme Metabolite Interactions
An example of both positive and negative regulation via enzyme-metabolite interactions
is the enzyme aspartate transcarbamylase (ATCase), which catalyzes the first committed step in

6

pyrimidine biosynthesis (Figure 1.5) in which carbamoyl phosphate is converted to N-carbamoyl
aspartate. When ATP is at high concentrations, the purine binds aspartate transcarbamylase
allosterically to activate the enzyme. This increases the flux through the pathway and, ultimately,
the production of the downstream product, CTP. Alternatively, at low concentrations of ATP,
aspartate transcarbamylase will still catalyze the reaction, but at a slower rate [13]. Aspartate
transcarbamylase is also negatively regulated via feedback inhibition by CTP. When the CTP
concentration is high, it binds aspartate transcarbamylase allosterically, inhibiting the enzyme,
and decreasing synthesis of pyrimidines. Once the concentration of CTP decreases this inhibition
is alleviated [14, 15].

Figure 1.5. Schematic of the Activation and Inhibition of ATCase. The downstream product of
pyrimidine synthesis, CTP, negatively regulates aspartate transcarbamylase. ATP increases
activity of aspartate transcarbamylase.
7

Regulation by enzyme-metabolite interactions has three major benefits. First, it is an
immediate reaction to the cellular environment. Second, this type of inhibition is reversible, as
once the concentration of regulatory metabolites decreases, they will no longer affect an enzyme.
Third, a metabolite inhibiting or activating an enzyme requires no unnecessary energy
expenditure, unlike regulatory mechanisms previously described.
1.2 Acetyl-CoA Carboxylase
The extent of regulation on an enzyme is dependent upon the role that enzyme plays in
the network of metabolic regulation [3]. Some enzymes are so critical to cell function that the
cell must rely upon multiple forms of regulation to control the growth rate of the cell. This
dissertation focuses on one enzyme that requires several forms of regulation: acetyl-CoA
carboxylase (ACC), which catalyzes the first committed step in fatty acid synthesis [16]. To
understand the multiple ways in which ACC is regulated it is important to first understand the
structure and function of the enzyme.
1.2.1 Background
Acetyl-CoA carboxylase catalyzes the ATP-dependent carboxylation of acetyl-CoA to
form malonyl-CoA. In most Gram-negative and Gram-positive organisms, catalysis requires the
formation of a macromolecular complex composed of three distinct proteins: biotin carboxylase
(BC), carboxyltransferase (CT), and biotin carboxyl carrier protein (BCCP) [16, 17].
Carboxylation of acetyl-CoA by ACC takes place via two half-reactions. In the first half-reaction
BC catalyzes the carboxylation of biotin, covalently linked to BCCP. In the second half-reaction
CT catalyzes the transfer of the carboxyl group to acetyl-CoA, forming malonyl-CoA (Scheme
1.1). Though a complex is required for catalysis of the overall reaction, both BC and CT can be
isolated and will retain their activity when assayed individually [16, 17].
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Scheme 1.1. Acetyl-CoA Carboxylase Reaction
1.2.2 Biotin Dependent Enzymes
Acetyl-CoA carboxylase belongs to a class of enzymes referred to as biotin dependent
enzymes [18]. These enzymes proceed via two half-reactions and require the cofactor biotin, also
known as vitamin H or B7 [18].
1.2.2.1 Structure of Biotin
The vitamin biotin is a bicyclic compound, composed of an ureido ring, a valeric acid
side chain, and a tetrahydrothiophene ring (Figure 1.6). The rings are fused in a cis conformation
with respect to each other, while the valeric acid side chain is cis to the ureido ring. The structure
of biotin contains three chiral carbons, which gives a possible eight isomers of the vitamin,
however, only (D)-+- biotin is active in nature (Figure 1.6).

Figure 1.6. Structure of (D)-+-Biotin.
1.2.2.2 Classifications of Biotin Dependent Enzymes
There are three classes of biotin dependent enzymes in bacteria: class I carboxylases,
class II decarboxylases, and class III transcarboxylases [18]. Most biotin dependent enzymes are
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class I, which is defined by both the enzymes’ fixation of carbon dioxide, and a distinct catalytic
mechanism, which includes a carboxyphosphate intermediate [18]. Acetyl-CoA carboxylase is a
class I biotin dependent enzyme. The decarboxylases (class II enzymes) catalyze the removal of
a carbonyl group from a substrate, which is then released as bicarbonate [18]. These enzymes are
found in anaerobic bacteria and are involved in pumping sodium out of the cell without the use
of ATP [18]. Currently, there is only one known enzyme in class III, which is methylmalonylCoA oxaloacetate transcarboxylase. This enzyme is involved in the production of propionic acid
in Propionibacterium shermanii [19]. Transcarboxylase is unique as it does not use or release
free CO2 [18], i.e., the carbon dioxide group is attached to methylmalonyl-CoA, transferred to the
biotin on the enzyme, and then transferred to pyruvate to form oxaloacetate.
1.2.3 Subunits of Acetyl-CoA Carboxylase
1.2.3.1 Biotin Carboxylase
1.2.3.1.1 Three-Dimensional Structure of Biotin Carboxylase
Biotin carboxylase catalyzes the first half-reaction of ACC (Scheme 1.1). The crystal
structure of the BC subunit was solved in 1994 by Waldrop et al. [20] and was the first structure
of a biotin dependent carboxylase (class I). Several three-dimensional structures of biotin
dependent carboxylases have since been determined, and were found to share similar structural
features between eukaryotes and prokaryotes [20, 21].
The overall fold of BC places this enzyme in the ATPgrasp superfamily of enzymes.
ATPgrasp enzymes typically fold into three domains referred to as either the A-, B-, and Cdomains or the N-terminal, central, and C-terminal domains [18]. The three-dimensional
structure of BC from E. coli revealed this enzyme folds into three domains, an A-domain, a Bdomain, and a C-domain [20]. While the A- and C-domains are located next to each other
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(Figure 1.7 A, Dark Purple and Light Purple), the B-domain is separate from the main structure
of the enzyme (Figure 1.7 A, Yellow). This gives the BC subunit a clam-like shape, which
allows for the B-domain to be mobile. When ATP binds during catalysis, the B-domain rotates
45o, closing over the active site (Figure 1.7 B) thereby isolating the active site pocket [18].
A.

A.)

B.)
B.

450

Figure 1.7. Structure of Monomeric Biotin Carboxylase Subunit of Acetyl-CoA Carboxylase in
E. coli. The A-, B- and C-domain are dark purple, yellow, and light purple, respectively. A.
Structure of the biotin carboxylase in the absence of substrates. The B-domain is in the open
position B. Structure of biotin carboxylase in the presence of ATP. The B-domain (yellow)
moves 45° to close over the active site when bound to the nucleotide. ATP is depicted in blue in
the active site pocket.
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1.2.3.1.2 Catalytic Mechanism of Biotin Carboxylase
The substrates of the first half-reaction, catalyzed by BC, follow a sequential ordered
kinetic mechanism, meaning all substrates must bind to the enzyme for catalysis to occur [22].
While ATP and bicarbonate bind in a random order, the substrate biotin binds third. As is
common in class I carboxylases, the mechanism of catalysis involves the formation of a
carboxyphosphate intermediate [18]. This intermediate forms when an electron pair on an
oxygen of bicarbonate attacks the gamma phosphorous atom of ATP.
Though the mechanism for the formation of the carboxyphosphate has been determined,
there are two postulated mechanisms for the transfer of the carboxyl group from
carboxyphosphate to the N1′ of biotin [23]. In the first mechanism, the carboxyphosphate
intermediate spontaneously decomposes forming phosphate and CO2, and the electron pair on the
phosphate anion abstracts the proton from the N1′ of biotin, generating an enolate intermediate.
The enolate intermediate then attacks the carbon atom of CO2, forming carboxybiotin. In the
second mechanism, the carboxyphosphate intermediate participates in substrate assisted
catalysis, where the electrons on the bridging oxygen atom of carboxyphosphate deprotonate the
N1′ of biotin. The resulting enolate then attacks the carbon atom of the carboxyl group to form a
dianionic tetrahedral intermediate. Originally, the first mechanism was generally agreed upon
despite the lack of experimental evidence, due to the strong electrophilic properties of CO2.
However, comparison of the three-dimensional structures of the BC subunit bound to either
phosphate or the biotin analogue N1’-methoxycarbonyl biotin methyl ester indicate the second
mechanism is more likely [24]. The crystal structure of phosphate bound to BC revealed the
residues that stabilize the phosphate are positively charged [18]. When BC was crystallized in
the presence of the biotin analog, the methyl ester group, which corresponds to the carboxyl
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group of carboxybiotin, was found to bind in the phosphate binding site and interact with the
same positively charged residues [24]. As these residues have already been shown to bind the
dianionic tetrahedral phosphate, it is likely these same residues stabilize the dianionic tetrahedral
intermediate that occurs in the second mechanism. In further support of the second mechanism,
other members of the ATPgrasp superfamily have been shown to proceed via direct attack on the
carboxyphosphate intermediate [25].
Structural studies of BC in the presence of the ATP analogue, AMPPCP, and in the
absence of biotin indicate that the location of the substrates in the active site aids in catalysis of
BC [24]. When ATP is present, and biotin absent, ATP is 5.8 Å from bicarbonate, ensuring that
in the absence of biotin there is no appreciable hydrolysis of ATP. Thus, for catalysis to occur
the distance between bicarbonate and ATP must be decreased. It is possible that “compression”
of the substrates occurs upon biotin binding, which would facilitate the activation of bicarbonate
to the carboxyphosphate intermediate. Structural studies also helped to explain a phenomenon
exhibited by BC: substrate induced synergism. Though BC exhibits a bicarbonate dependent
ATPase that can be measured in the absence of biotin, the binding of biotin increases ATPhydrolysis 1000-fold [26]. This increase in activity could be due to “compression” of the
substrates bicarbonate and ATP, upon the binding of the third substrate biotin [24].
1.2.3.1.3 Quaternary Structure of Biotin Carboxylase in E. coli, and the Implications for
Catalysis
Biotin carboxylase in E. coli forms a homodimer (Figure 1.8) in which the monomers
contain structurally independent active sites [20]. These active sites alternate during catalysis,
and exhibit negative cooperativity, meaning one active site must complete a reaction in its
entirety before the active site on the opposing monomer can be utilized [27]. This was observed
when a kinetically inactive mutant monomer of BC was paired with a wild type (and therefore
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catalytically active) monomer of BC and tested for activity. If the active sites acted
independently there would have been a 50% decrease in activity observed as the active monomer
would continue to catalyze the reaction unimpeded by the inactive monomer. Studies showed,
however, that there was a 96% decrease in activity, indicating the active sites do not act
independently, but activity of the enzyme is limited by the activity of the slowest monomer [27].

Figure 1.8. Three-Dimensional Structure of the BC Homodimer. The monomers of BC are
yellow and green.
1.2.3.2 Carboxyltransferase
1.2.3.2.1 Three-Dimensional Structure of Carboxyltransferase
Carboxyltransferase catalyzes the second half-reaction in ACC (Scheme 1.1). The crystal
structure of the CT domain from yeast was determined in 2003 [28], and the bacterial threedimensional structure was determined in 2006 [29]. The yeast CT macromolecular structure is a
homodimer with each monomer containing two domains: an N-terminal domain and a C-terminal
domain [28]. These domains dimerize head-to-tail, with the N-terminal domain of one monomer
binding the C-terminal domain of the second monomer (Figure 1.9 A). In contrast, the
macromolecular structure of bacterial CT is composed of two different gene products which
form an α2β2 heterotetramer (Figure 1.9 B, Pink and Blue, respectively) [28]. The crystal
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structure of bacterial CT also showed the presence of a zinc finger domain, which is absent in the
eukaryotic CT [29].
A.

B.

Figure 1.9. Crystal Structures of Yeast and Bacterial Carboxyltransferase. A. Yeast
carboxyltransferase. One monomer is in blue, and the second monomer is in pink. The active
sites are denoted by the arrows. B. Staphylococcus aureus carboxyltransferase. The α subunit is
in pink while the β subunit is in blue. The active sites are denoted by the arrows.
Despite these structural differences, the yeast CT and bacterial CT share distinct
similarities. The tertiary structures of yeast CT and bacterial CT resemble each other, which is
unsurprising as the C-terminal and N-terminal domains of yeast CT mimic the α and β subunits
of bacterial CT, respectively. Furthermore, both the bacterial CT and yeast CT contain two active
sites that are located between the subunits indicated by the arrows in Figure 1.9. Crystal
structures indicate the N-terminal domain of yeast CT most likely binds acetyl-CoA, while the
C-terminal domain of yeast CT binds carboxybiotin [28]. This binding mechanism is mimicked
in bacteria, where the active sites for CT lie between the α and β subunits, with the α subunit
most likely binding carboxybiotin and the β subunit binding acetyl-CoA [29].
The overall fold of the structure of CT places this enzyme in the crotonase superfamily of
enzymes, which is characterized by the presence of a specific structural region, referred to as the

15

crotonase fold that contains an oxyanion hole, composed of two peptidic NH groups (Figure
1.10, Blue) [29]. Both the α and β subunits of bacterial ACC contain this fold, which suggests
that the proteins arose from gene duplication [30].
A.

B.

Figure 1.10. Crystal Structure of the Crotonase Fold from Bacterial Carboxyltransferase. A. The
α subunit (green) with the crotonase fold in blue. B. The β subunit (green) with the crotonase
fold in blue.
1.2.3.2.2 Catalytic Mechanism of E. coli Carboxyltransferase.
Though the exact catalytic mechanism of CT remains unknown, members of the
crotonase superfamily of enzymes are known to stabilize enolates, indicating that both acetylCoA and carboxybiotin form enolate anions as intermediates [29, 31]. Therefore, it is likely that
acetyl-CoA is deprotonated by a base in the active site of the β subunit to form an enolate ion
stabilized by the oxyanion hole in the crotonase fold. Simultaneously, the carboxybiotin
decomposes to also form an enolate anion stabilized by the oxyanion hole in the α subunit. Once
these anions are formed, the carbon of CO2 undergoes a nucleophilic attack from the enolate of
acetyl-CoA, thereby forming malonyl-CoA [18, 31].
The reaction catalyzed by carboxyltransferase in vivo is the transfer of the carboxyl group
from carboxybiotin onto acetyl-CoA (Scheme 1.1). Due to the instability of carboxybiotin,
however, the isolated carboxyltransferase reaction is assayed in the reverse direction in which
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malonyl-CoA is decarboxylated to produce acetyl-CoA. The substrates for CT follow an ordered
mechanism, with malonyl-CoA binding first followed by the biotin analogue, biocytin [32].
Biocytin is biotin with a lysine residue attached to the valeric acid side chain and is used because
the Vmax is 3-fold higher than when using biotin as a substrate [33]. As biotin is covalently linked
to BCCP via a lysine residue, the molecule biocytin mimics the biotin residue when attached to
BCCP. This suggests that CT preferentially binds the physiological form of biotin, thereby
lowering the likelihood of free biotin binding nonproductively to the CT subunit.
1.2.3.3 Biotin Carboxyl Carrier Protein
The third protein in bacterial ACC is the BCCP subunit, which contains the vitamin
biotin, covalently linked to residue K122 in E. coli [34]. Bacterial BCCP is composed of two
domains connected by a proline alanine rich linker, which causes the 16.7 kDa protein to migrate
high (22 kDa) on an SDS-PAGE gel [35]. These domains are the N-terminal domain, comprising
the first 71 residues of the protein, and the C-terminal domain, comprising the last 80 residues.
Though much is known about the C-terminal domain of BCCP, information pertaining to the Nterminal domain is minimal.
Currently, there is no structural data for full-length BCCP due in part to its tendency to
aggregate [36]. However, the three-dimensional structure of the bacterial C-terminal domain has
been determined via x-ray crystallography [37] and NMR [38, 39]. The structure of this domain
consists of two symmetrical halves made up of four-stranded anti-parallel beta sheets creating a
hydrophobic core (Figure 1.11) [37, 38, 39]. The determination of the three-dimensional
structure of the C-terminal domain of BCCP revealed the presence of a region that extends out
from the C-terminal domain consisting of residues Thr94-Ly100. This region was denoted the
‘thumb’ (Figure 1.11), due to its shape. The thumb region is absent from other forms of ACC,
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such as human ACC [40], as well as other biotin dependent enzymes, such as transcarboxylase
[41]. The purpose of the thumb has yet to be confirmed; however, there is data to suggest that the
thumb may be required for ACC catalysis, as deletion of the thumb led to a decrease in growth
rate [42]. An in vivo study, which demonstrated deletion of the thumb led to a decrease in the
product of ACC, malonyl-CoA, supports this theory [personal communication, Grover Waldrop].
Both the biotinylated and unbiotinylated structures of the C-terminal domain of bacterial
BCCP have been determined [37, 38, 39]. Comparison of these structures gave insight into the
effect of biotinylation on the protein. In the three-dimensional structure of the unbiotinylated Cterminal domain of BCCP in E. coli, the thumb was shown to be highly flexible [37, 38];
however, the three-dimensional structure for the biotinylated C-terminal domain of BCCP in E.
coli showed that biotinylation stabilized this region [39]. Furthermore, the biotin was shown to
interact via a hydrogen bond with residue Thr94 (Figure 1.11) [39].

Thumb

Figure 1.11. Crystal Structure of Biotinylated Biotin Carboxyl Carrier Protein from E. coli.
Biotin is blue, and the thumb is denoted on the structure.
As mentioned above, very little is known about the N-terminal domain of bacterial
BCCP. Though there is some evidence that this domain is involved in formation of the BCBCCP complex in E. coli [43] a crystal structure of BC bound to BCCP refutes this conclusion
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[44]. Furthermore, there is no structural data available for the NTD, most likely due to its
propensity to aggregate [36], which is similar to full-length BCCP [43, 45]. Interestingly, though
most eukaryotic BCCP contain a domain homologous to the C-terminal domain in bacteria, there
is no homologue to the N-terminal domain.
1.3 Quaternary Structure of Acetyl-CoA Carboxylase
1.3.1 Bacterial Quaternary Structure of Acetyl-CoA Carboxylase
Currently, there is no three-dimensional structure of ACC in toto; however, the threedimensional structure of the BC-BCCP complex in E. coli was published by Broussard et al.
[44]. To obtain the protein, BC and BCCP were overexpressed extragenomically and purified via
His-tag on the N-terminus of BCCP. The purified protein complex was then crystallized, and the
three-dimensional structure determined.
In the complex, the ratio of BC to BCCP is 1:1, consisting of four BC subunits and four
BCCP subunits (Figure 1.12 A). The BC homodimers (Pink and Blue) form a homotetramer that
are fitted together at a 45° angle (Figure 1.12 B), and are held together by the C-terminal domain
of BCCP (Yellow, Green and Blue), which act as molecular clips. In this structure, there was no
electron density for the N-terminal domain of BCCP, despite the fact that full-length BCCP had
been overexpressed. To confirm the N-terminal domain was present and had not been cleaved,
the authors performed two assays. First, a crystal of the BC-BCCP complex was analyzed via
SDS-PAGE. The band for BCCP was visible at the correct molecular weight for the full-length
protein, indicating the N-terminal domain was present. Second, a Western blot was performed
using a His-tag antibody, targeting the His-tag on the N-terminus of BCCP. If the N-terminal
domain of BCCP had been cleaved, then the antibody would not have bound. Full-length BCCP
was visible, thus, the N-terminal His-tag was present, and by inference full-length BCCP.
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A.

B.

900

Figure 1.12. Three-Dimensional Structure of Bacterial Biotin Carboxylase-Biotin Carboxyl
Carrier Protein Complex. The two BC homodimers are in pink and blue. The four biotin
carboxyl carrier proteins are green, yellow, blue, and red. A. Side view of the complex. B. 90°
rotation view from the bottom of the complex. The BC homodimers are at a 45° angle to each
other, while the C-terminal domains of BCCP hold the BC homodimers together acting as
molecular clips.
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1.3.2 Eukaryotic Quaternary Structure of Acetyl-CoA Carboxylase
The crystal structure of eukaryotic ACC from yeast (Figure 1.13) shows that the enzyme
is a homodimer [46]. The structure is in the shape of a quarter of a disk with a large channel
through the center of the enzyme. This is proposed to be where the BCCP domain (Figure 1.13,
Blue) of strand one (space filling model) translocates to transfer the carboxybiotin moiety from
BC (Figure 1.13, Red) of strand one (space filling model) to CT (Figure 1.13, Pink).

BC

BCCP

CT

CT
Figure 1.13. Crystal Structure of the Homodimer of Yeast Acetyl-CoA Carboxylase. Chain one
is a space filling model (red BC (labelled), green BT, blue BCCP (labelled), yellow central
regions, and pink CT (labelled)) while chain two is in ribbons (red BC, green BT, blue BCCP,
yellow central regions, and pink CT.) The structure is in the shape of a quarter of a disk. The
channel where BCCP translocates is represented by an oval in the center of the diagram.
The three-dimensional structure revealed the presence of a previously unknown domain,
referred to as BT (Figure 1.13, Green). The BT domain is located between the BC and CT
domains of the same protomer to facilitate interactions between the catalytic domains. The BT
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domain in yeast ACC is similar in both structure and function to the BT domain in propionylCoA carboxylase, a biotin dependent enzyme involved in odd chain fatty acid oxidation [47].
The three-dimensional structure of yeast ACC also reconciled two seemingly conflicting
observations of eukaryotic BC. When the gene coding for the BC domain from yeast is
overexpressed and purified, it is a catalytically inactive monomer [21]. Alternatively, when the
gene coding for the holoenzyme of ACC (the entire polypeptide chain including BC, CT, and
BCCP) is overexpressed and purified, the BC domains on opposing protomers form a
homodimer similar to that of E. coli BC [20, 46]. The interaction of the BC domains from
opposing protomers induces a conformational change in BC, causing it to become catalytically
active. Why the BC domain, when overexpressed and purified separately, is found as a monomer
is not known, however, it is hypothesized that the BC-BC interface has weak interactions, which
are overcome when the rest of the polypeptide is present [46].
1.4 Metabolic Regulation in Acetyl-CoA Carboxylase
1.4.1 Regulation of Bacterial Acetyl-CoA Carboxylase
1.4.1.1 Transcriptional Regulation of Biotin Carboxylase-Biotin Carboxyl Carrier Protein
The BCCP subunit was found to regulate transcription of the genes coding for BC (accC)
and BCCP (accB), which are located in an operon in E. coli (accBC) at 73.35 min [36]. James
and Cronan report that overexpression of BCCP extragenomically represses production of the
native transcript of the accBC operon. In contrast, if the plasmid contains both accB and accC,
there is no reduction of native transcript, indicating that transcription levels are only downregulated in the event that BCCP is at a higher concentration than BC. Furthermore,
overexpression of the gene coding for the isolated C-terminal domain of BCCP has no effect on
the level of accBC transcript, whereas overexpression of the gene coding for the isolated N-
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terminal domain of BCCP represses production of the native transcript. Therefore, the Nterminal domain of BCCP regulates the stoichiometric ratios of two major components of ACC
[36]. Though the mechanism of repression is not known, it is unlikely BCCP interacts directly
with the native promoter [personal communication, Grover Waldrop].
1.4.1.2 Translational Regulation of Carboxyltransferase
Carboxyltransferase down-regulates its own translation by binding the mRNA for the α
and β subunits via the zinc finger domain [48]. It is important to note that the α and β subunits of
CT are located on opposite ends of the genome in E. coli (at 4.5 min and 52.4 min, respectively),
and thus have distinct mRNAs [49]. During log phase, when acetyl-CoA concentrations are high,
CT preferentially binds acetyl-CoA over its mRNA. Alternatively, when acetyl-CoA
concentrations are low (for example during stationary phase), the CT subunit binds the mRNA of
the α and β subunit competitively versus the substrate acetyl-CoA [48]. Carboxyltransferase
binding its mRNA has a three-fold effect. First, by binding the mRNA, CT is down-regulating its
own translation, therefore preventing wasteful energy expenditure in the absence of acetyl-CoA.
Second, CT binding the mRNA of the α and β subunit ensures both subunits are produced at a
stoichiometric ratio, despite being located at two distinct loci in the genome. Third, mRNA
inhibits catalysis of the CT subunit, thus down-regulating fatty acid synthesis during stationary
phase. Thus, CT acts as a “dimmer switch” allowing the cell to respond to changes in acetyl-CoA
concentrations [48].
1.4.1.3 Regulation of the Macromolecular Complex
Acetyl-CoA carboxylase is also regulated via feedback inhibition by acyl-ACPs which
are the downstream intermediates of fatty acid synthesis (FAS) [50]. At high concentrations of
acyl-ACPs, ACC was down-regulated to a maximum amount of 70%, indicating that high
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concentrations of acyl-ACPs cannot completely abolish ACC activity. This mechanism causes
fatty acid synthesis to significantly decrease, while still maintaining a minimal amount of fatty
acid production.
The macromolecular structure of bacterial ACC was found to exhibit substrate induced
synergism [17] meaning acetyl-CoA must be present for ATP hydrolysis to occur. This
regulation prevents wasteful hydrolysis of ATP when acetyl-CoA concentrations are low, such as
in stationary phase or starvation.
1.4.2 Regulation of Acetyl-CoA Carboxylase in Humans
1.4.2.1 Background
In humans, there are two isoforms of ACC: ACC1 and ACC2. As in most eukaryotes, the
proteins for human ACC (BC, BCCP, and CT) are organized into domains on a single
polypeptide chain [18]. ACC1 is a 265 kDa protein located in the cytosol and is expressed in
greater amounts in lipogenic tissue, such as the mammary glands, and adipose tissue [51]. ACC2
is a 280 kDa protein located in the mitochondria, and is expressed at higher concentrations in
oxidative tissues, such as the heart and skeletal muscle [52]. Both ACC1 and ACC2 are also
expressed in high concentrations in the liver.
Just like in bacteria, ACC in humans catalyzes the ATP-dependent carboxylation of
acetyl-CoA to form malonyl CoA; however, the role of the two isoforms differs greatly.
Malonyl-CoA produced by ACC1 proceeds into fatty acid synthesis in the cytoplasm.
Alternatively, malonyl-CoA produced by ACC2 acts as an inhibitor to the enzyme carnitine
palmitoyl transferase, which is the enzyme responsible for transporting fatty acids into the
mitochondria to be broken down by fatty acid oxidation. Both isoforms of human ACC are
highly regulated.
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1.4.2.2 Regulation of Polymerization of Human Acetyl-CoA Carboxylase
Activity of both ACC1 and ACC2 are increased by polymerization of the enzymes [53].
In the fed state, citrate levels in the cell increase dramatically, upregulating polymerization of the
enzyme which increases activity of ACC up to 50% [54]. This polymerization has a twofold
effect. First, via ACC1, this increases the production of fatty acids, which can then be stored for
energy. Second, via ACC2, this decreases degradation of fatty acids from fatty acid oxidation,
preventing the utilization of stored energy. Alternatively, polymerization of ACC1 is inhibited by
high concentrations of palmitoyl-CoA, the end product of FAS [55]. Thus, if there is an
abundance of product from FAS, the flux through the pathway is down-regulated, causing a
decrease in fatty acid production via ACC1. As accumulation of palmitoyl-CoA is only in the
cytosol, high levels of palmitoyl-CoA do not affect ACC2, meaning that ACC2 will not be
down-regulated, and transfer of fatty acids into the mitochondria does not increase.
1.4.2.3 Regulation by Phosphorylation of Human Acetyl-CoA Carboxylase
Activity of ACC1 and ACC2 is also inhibited by phosphorylation when nutrients are
scarce [56]. When glucose levels are low, and/or during starvation AMP levels increase leading
to the activation of AMP-activated kinase (AMPK), which phosphorylates ACC1 and ACC2,
thereby inhibiting activity [57]. This down-regulation of ACC1 allows the cell to halt fatty acid
synthesis, while down-regulating ACC2 alleviates the inhibition on carnitine acyl transferase,
thus increasing transport of excess fatty acids into the mitochondria to be oxidized and used for
energy.
There are eight reported phosphorylation sites on ACC1 and ACC2 [47]. Though the
mechanism of inhibition for most of the sites is unknown, the purpose of the phosphorylation site
Ser80 on ACC1 and Ser222 on ACC2 has been reported [47]. Ser80 on ACC1 and Ser222 on
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ACC2 are located on the BC-BC interface of their respective isoforms. As noted above, the BC
domain in eukaryotes is only catalytically active when interacting with another BC domain to
form a dimer [21]. When the serine residues located on the interface are phosphorylated, activity
is inhibited because the BC domain on one protomer of the holoenzyme is prevented from
interacting with the other BC domain on the second protomer of the holoenzyme. Alternatively,
dephosphorylation allows the BC domains on opposing protomers to interact thereby becoming
catalytically active [47]. Ser80 on ACC1 or Ser222 on ACC2 is most likely a target due to the
fact that the interactions holding the BC-BC domains together are weak. Therefore, it is possible
that in the holoenzyme the BC domains of strand one and two associate and disassociate
continuously, allowing access to Ser80 on ACC1 and Ser222 on ACC2.
This type of regulation is also exhibited on Ser 1157 in yeast [58]. Interestingly, the
natural product soraphen A has been shown to inhibit yeast BC by binding in the BC-BC
interface of acetyl-CoA carboxylase. In fact, the soraphen A binding site includes Ser1157,
indicating that this mechanism of inhibition prevents the BC-BC interactions, which is consistent
with the regulatory mechanism of phosphorylation/dephosphorylation.
1.4.2.4 Transcriptional Regulation of Human Acetyl-CoA Carboxylase
The regulation of ACC1 at the transcriptional level is based on control of three promoters
(PI, PII, and PIII) [59]. All three promoters are activated by insulin and the synthetic
glucocorticoid dexamethasone [60]. Though the mechanism is not well understood, both insulin
and glucocorticoids are well documented to have an anabolic effect on lipid metabolism [60],
thus the finding that these hormones activate ACC1 is unsurprising. The PI and PII promoter are
active in all human tissue, whereas the PIII promoter is active in the heart, brain, skeletal muscle,
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and adipose tissue [59]. PI is constitutively expressed, while PII and PIII are subject to control
based on diet and hormones [59].
One example of transcriptional regulation in ACC1 is the binding of sterol regulatory
element binding protein-1a (SREBP-1a) to the PII promoter [59]. SREBP-1a is a member of the
SREBP family of enzymes, and is attached to the endoplasmic reticulum. At low levels of
sterols, such as cholesterol, this protein is cleaved from the ER and binds to the sterol regulatory
element DNA sequence, located in the PII promoter. Conversely, high concentrations of sterols,
such as cholesterol, prevent cleavage from the nuclear membrane, thus preventing activation of
ACC1 transcription. The physiological implication for this regulation is not well understood in
human ACC1. It is interesting to note, however, transcription of the gene coding for the first
committed step in cholesterol biosynthesis, HMG-CoA reductase, is similarly activated by
SREBP-1a [61]. As cholesterol biosynthesis also begins with acetyl-CoA, it is possible there is
some evolutionary connection between the two.
ACC2 has also been shown to have three promoters (P0, PI, and PII); however, only PI
and PII are functional in vivo [52]. PI is highly active in skeletal muscle and the heart, while PII
is the primary promoter in the liver [62]. As with ACC1, PII in ACC2 is activated by insulin,
glucocorticoids, and SREBP-1a [62].
The promoters in both ACC1 (PI, PII, and PIII) and ACC2 (PI, PII) are subject to
activation by a second sterol regulatory element binding protein, SREBP-1c [63]. SREBP-1c is a
member of the same family as SREBP-1a, and is also activated by cleavage from the
endoplasmic reticulum. SREBP-1c has been shown to similarly activate transcription of the
enzymes required for triglyceride biosynthesis. This means the flux through FAS and the
triglyceride biosynthesis pathway increase concomitantly.
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1.4.2.5 The Role of DNA Secondary Structures in Regulation of ACC1
DNA replication and transcription of ACC1 is negatively regulated by the formation of
secondary structures in the promoters PI and PII, due to their rich G/C content. The high
concentration of G and C allows the formation of a cube-like structure (Figure 1.14) from four
guanines or four cytosines. These are referred to as the G-quadruplex, which forms in the
template strand (Figure 1.14 A), and I-motif, which forms in the non-template strand (Figure
1.14 B) [64, 65]. Formation of the G-quadruplex in ACC1 occurs spontaneously under
physiological conditions, and has been shown to prevent DNA replication aided by TMPyP4, a
small molecule which is known to stabilize G-quadruplexes [66]. Furthermore, formation of the
G-quadruplex represses transcription by preventing transcription factors from binding such as
Sp1, a protein that activates transcription of ACC1 [59]. Similar to the G-quadruplex, the I-motif
also forms spontaneously; however, stability of this motif has been shown to increase when
subjected to acidic conditions, high salt concentrations, negative DNA supercoiling, and
molecular crowding (i.e. when the number of small molecules is high compared to the space and
water supply available) [65]. Like the G-quadruplex, the I-motif secondary structure was also
shown to inhibit DNA replication, as well as transcription of ACC1. This mechanism of
regulation is most likely utilized to aid in the transition between log phase, when the cell
replicates rapidly and ACC1 is overexpressed in abundance, to the stationary phase, when DNA
synthesis and ACC1 transcription are down-regulated.
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B.

Figure 1.14. Drawings Representing the G-Quadruplex and I-Motif of PII in Human ACC1. A.
G-quadruplex from the PII promoter of human ACC. The white represents unbound bases, and
the red represent the guanosines forming the complex. Arrows in the structure indicate
orientation of the strands. From Kaulage et al. [64] B. I-motif from the PII promoter of human
ACC. The yellow are cytosines forming the structure, and the red are unbound bases. The arrows
in the structure represent the direction of the strands. From Kaulage et al. [65].
1.5 Acetyl-CoA Carboxylase as a Novel Target for Antibiotics
1.5.1 Background
The major conclusion that can be taken from the various ways in which ACC is regulated
in both human and bacteria is that the cell is able to regulate its metabolism to ensure the cell
remains in homeostasis. The mechanisms of regulation mentioned above have thus far only been
in response to changes in the availability of nutrients in the cellular environment. The growth
rate of the cell can also be forcibly decreased by foreign toxins such as antibacterial agents.
However, over time, a cell line will eventually augment its own genome to overcome these
foreign toxins, creating a resistant strain.
The WHO categorizes antibacterial resistance as one of the biggest threats to the modern
world [66]. Though resistance occurs naturally, the process has been accelerated by the over
prescription of antibiotics and the excessive use in agricultural practices. Thus, new antibacterial
agents are in constant demand. Unfortunately, development of antibiotics over the last 30 years
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has concomitantly decreased [67], and as a result, a ‘post antibiotic era’ is rapidly approaching,
where common infections will once again be deadly [68]. Knowing this, scientists have begun
research into novel antibacterial targets.
The development of an effective antibacterial agent with low side effects must fulfill
three requirements: first, the antibacterial agent must be specific to the bacterial target, and
therefore not affect, or only minimally affect, the eukaryotic homologue; second, the
antibacterial agent must have the ability to affect both Gram-negative and Gram-positive bacteria
(i.e. be broad spectrum); and third, the effect of the antibacterial agent must be either bactericidal
or bacteriostatic [69]. The fatty acid synthesis (FAS) pathway in bacteria meets all three
conditions. The enzymes involved in FAS in eukaryotes are located on a single polypeptide
chain, whereas in bacteria these enzymes are distinct gene products [16, 18], thus any
antibacterial agent that targets the bacterial proteins would most likely not affect the eukaryotic
proteins. Furthermore, the enzymes in FAS from many human pathogens share homology and
biochemical properties, indicating that an antibacterial agent has the opportunity to be broad
spectrum [70]. Finally, the product of FAS, palmitoyl-CoA, is used in membrane biogenesis,
thus the inhibition of this pathway would be bactericidal.
As ACC plays a critical role in FAS, inhibitors of this enzyme could be used as novel
antibacterial agents. ACC was first validated as a target when Pfizer determined that a mutation
in the CT subunit of ACC caused a mutant strain of Staphylococcus aureus to be temperature
sensitive, indicating that ACC is critical for cell growth [personal communication, Grover
Waldrop]. GlaxoSmithKline confirmed this when they were unable to make a mutant strain of
bacteria lacking the ACC gene [personal communication, Grover Waldrop]. There are currently
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no commercially available antibacterial agents targeting ACC, making it an ideal target for novel
antibacterial agent development.
1.5.2 Biotin Carboxylase Inhibitors
The discovery of the first antibacterial agents targeting the biotin carboxylase subunit of
ACC was unintended [71]. Scientists at Pfizer were screening whole cells against a library of 1.6
million potential anti-cancer compounds that targeted tyrosine protein kinases when a class of
compounds, referred to as the pyridopyrimidines, were found to exhibit antibacterial activity
against Gram-negative bacteria and the Gram-positive bacterium Staphylococcus aureus. The
potency of the pyridopyrimidines was significantly less for S. aureus, indicating specificity for
Gram-negative pathogens. One of these compounds (compound 1) was determined to have a low
Kd of 0.8 nM, and was used for further studies (Figure 1.15). In order to determine the target of
this antibacterial activity, spontaneous mutations were generated in the Gram-negative pathogen
Haemophilus influenza. Interestingly, the mutant strains that were shown to be resistant to the
pyridopyrimidines all had mutations in the gene coding for the BC subunit of ACC. When the
mutations were compared with the crystal structure for E. coli BC bound to ADP, it was found
that the mutations were clustered in the ATP active site; this was unsurprising, given the original
screening library targeted kinases, which also hydrolyze ATP. The three-dimensional structure of
biotin carboxylase bound to compound 1 confirmed that compound 1 bound in the ATP site of
BC. Furthermore compound 1 was shown to interact with isoleucine 437 in E. coli BC, whereas
the resistant mutant strains contained a threonine at this residue, which causes a decrease in
hydrophobic interactions between the inhibitor and the BC enzyme. The equivalent residue to
437 in Gram-positive bacteria is also a threonine, indicating why compound 1 is more potent
versus Gram-negative bacteria.
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Compound 1
Figure 1.15. Structure of Pyridopyrimidine Inhibitor of Biotin Carboxylase.
The discovery of the pyridopyrimidines led to further investigation into biotin
carboxylase inhibitors [72]. Using a virtual screen of 2.2 million compounds, 525 compounds
were found to share pharmacophore features with compound 1 [72]. Of these compounds, 48
inhibited BC with an IC50 value of less than 10 µM. In the same study, a biochemical screening
of 5200 fragments (molecules with a MW of 250 kDa or less) were analyzed, giving a total of
142 fragments that inhibited BC with IC50s in the micromolar range. Comparison of the
compounds from both screens found that all compounds shared hydrogen bond donors and
acceptors similar to those in compound 1. These similarities are circled on compound 1 and one
of the compounds from these screens, an amino-oxazole derivative, denoted as compound 2, in
Figure 1.16. A crystal structure of compound 2 bound to BC, revealed that the compound bound
in the ATP binding site of BC in the same manner as the pyridopyrimidines. Studies also showed
that compound 2 did not inhibit eukaryotic ACC, or 40 protein kinases tested, indicating that it is
highly specific to the bacterial BC subunit.
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Compound 1

Compound 2

Figure 1.16. Inhibitors of Biotin Carboxylase. 1 Pyridopyrimidine 2 Amino-oxazole derivative.
Pharmacophore similarities between the compounds are circled.
Though fragment based screening has the advantage of testing large libraries of
compounds, most compounds bound with low affinity [73]. In order to increase the potency of a
potential antibacterial agent, fragment-to-lead optimization was employed. While compound 1
was shown to bind more tightly to BC than the amino-oxazole derivative, compound 2 is more
synthetically tractable and therefore was used to discover more potent inhibitors of BC. By
extending the amino-oxazole derivative as in compounds 3 and 4 (Figure 1.17), Pfizer was able
to maximize interactions with the ATP binding site, giving rise to inhibitors with 200- and 3000fold higher IC50 values, respectively [72].
In a separate study by Cheng et al. a third class of compounds was found to inhibit the
BC subunit in bacterial ACC [74]. This class of compounds is referred to as the benzimidazole
carboxamides. Crystallographic studies of the benzimidazole carboxamides bound to BC showed
that these inhibitors also bind in the ATP site. However, unlike both the pyridopyrimidines and
amino-oxazole, the benzimidazole carboxamides were found to have the added benefit of being a
broad spectrum antibacterial. Furthermore, this class of antibacterial agents did not affect
eukaryotic ACC, protein biosynthesis, or human kinases, indicating this class of inhibitors has
high specificity for bacterial BC.
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Compound 3

Compound 4

Figure 1.17. Hit-to-Lead Results of Inhibitors of Biotin Carboxylase. 3 Amino-oxazole 4
Amino-oxazole derivative.
1.5.3 Carboxyltransferase Inhibitors.
1.5.3.1 Inhibiting Carboxyltransferase via the Active Site
Unlike BC, there is only one class of compounds that has been shown to inhibit the
carboxyltransferase subunit of CT and have antibacterial activity. This class of compounds is
referred to as the pyrrolidinediones, which are characterized by the pyrrolidinedione head group
(Figure 1.18, Compound 5) [75]. The first of this class of inhibitors discovered was the natural
product andrimid, (Figure 1.19, compound 6) which was found in the broth culture of an
Enterobacter sp., an intracellular symbiont of the brown planthopper insect. Andrimid was
determined to be bactericidal versus Xanthomonas campestris pv. oryzae, a pathogen that is
lethal to rice plants, on which the brown planthopper feeds [76].

Compound 5
Figure 1.18. 5 Pyrrolidinedione Head Group.
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In a subsequent study, Needham et al. found that an isolate of Pseudomonas fluorescens
was potent against methicillin resistant Staphylococcus aureus (MRSA) [77]. Examination of the
isolate revealed that it contained the compound andrimid, as well as the compounds moiramide
A, B, and C (Figure 1.19, Compounds 7, 8, and 9 respectively). Of the three moiramide
derivatives, only moiramide B (compound 8) was shown to have antibacterial activity; this was
unsurprising as moiramide B and andrimid possess the same pyrrolidinedione head group, only
varying in the length of the fatty acyl tail. Alternatively, moiramide C (compound 9), which
differs by a single functional group attached to the pyrrolidinedione head, did not exhibit
antibacterial activity, indicating that while the fatty acyl tail may be subjected to significant
alterations, the chemical components of the head group are more rigidly controlled. This is in
agreement with a study by Pohlmann et al. in which the authors conducted a structure activity
relationship on the head group and found that the pyrrolidinedione head could not withstand
alterations and retain antibacterial properties [78].

Compound 6

Compound 7

Compound 8

Compound 9

Figure 1.19. Pyrrolidinedione Compounds Found in the Broth Culture of an Enterobacter sp. 6
Andrimid. 7, 8, and 9 Moiramide A, B, and C, respectively.
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Kinetic studies revealed that both andrimid and moiramide B were inhibitors of the CT
subunit of ACC, with moiramide B being the more potent inhibitor [76, 77]. Moiramide B was
shown to have IC50s in the nanomolar range against the CT subunit of ACC in both Gramnegative and Gram-positive organisms. In contrast, moiramide B did not affect eukaryotic ACC,
indicating it could be used as a new broad spectrum antibacterial agent; however, there are no
studies published on the activity of this compound in vivo.
A crystal structure of moiramide B (compound 8) bound to the CT subunit from
Staphylococcus aureus revealed that compound 8 binds in the active site, which is at the
interface of the α and β subunits. This is consistent with the fact that moiramide B exhibits
competitive inhibition versus malonyl-CoA [77]. The head group (Figure 1.20, Compound 8) of
moiramide B forms hydrogen bonds with glycine 208, alanine 168, glycine 166, and glycine 232
of the β subunit, and serine 198 of the α subunit [79]. These residues are conserved between
Gram-negative and Gram-positive organisms, which explains why moiramide B is a broad
spectrum antibacterial agent [28, 30]. Furthermore, glycine 208 is part the oxyanion hole of the β
subunit involved in stabilizing the acetyl-CoA enolate anion. When moiramide B binds the
carboxyltransferase subunit, the amide hydrogen of Gly208 interacts with both the C2 and C5
carbonyl groups on the pyrrolidinedione head, which are circled in Figure 1.20. Conversely, the
fatty acyl tail was shown to have weak interactions with CT. Structure activity relationships of
moiramide B in which the fatty acyl tail was deleted (compound 10), showed little difference in
inhibition between the two compounds. However, compound 10 was shown to have no
antibacterial activity, indicating that the fatty acyl tail is most likely only involved in the
transport of the molecule into the bacterial cell. This confirms the results by Pohlmann et al. that
the fatty acyl tail is not required for inhibition [78, 79].
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Head Group
Compound 8

Compound 10

Figure 1.20. Moiramide B and Compound 10. Head group of moiramide B is labelled.
1.5.3.2 Inhibiting Carboxyltransferase via the Zinc Finger Domain
The carboxyltransferase subunit of bacterial ACC also contains a zinc finger domain
separate from the active site [28]. This domain has been shown, as previously noted, to bind the
mRNA of CT competitively versus the substrate acetyl-CoA [48], indicating the active site and
the zinc finger domain communicate. As the zinc finger domain is present in both Gram-negative
E. coli and Gram-positive Staphylococcus aureus CT [28] but absent from eukaryotic ACC [27],
an inhibitor which binds the zinc finger domain could lead to the discovery of novel antibacterial
agents that are both broad spectrum and specific to bacterial ACC.
1.5.4 Acetyl-CoA Carboxylase Complex Inhibitors
As mentioned above, ACC has been shown to form a complex that is required for
catalysis [17]. This discovery leads to the possibility for the development of antibacterial agents
that inhibit the protein-protein interactions between the subunits. These types of inhibitors would
be specific to bacterial ACC because eukaryotic ACC is on a single polypeptide chain, and
therefore most likely does not contain these same protein-protein interactions (PPI). Though
there is not a three-dimensional structure of bacterial ACC in toto, the BC-BCCP complex
(Figure 1.12) may be used as a template to begin development of novel antibacterial agents,
which target these interactions [44].
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1.5.5 Development of Dual Ligand Inhibitors versus Acetyl-CoA Carboxylase to Mitigate
Antibacterial Resistance.
The major issue with all antibacterial agents is the inevitability of genetic mutations
which lead to antibacterial resistance. Though this occurrence cannot be abrogated completely,
dual-ligand inhibitors have been shown to lower the frequency of resistance [80, 81, 82]. Dualligand inhibitors are chemical compounds that consist of two inhibitory moieties, linked by an
aliphatic chain, where each moiety inhibits distinct proteins. Thus, the frequency of resistance
decreases as missense mutations would have to occur in more than one gene to abolish
inhibition. Being that ACC contains two enzymatic subunits (BC and CT), which are coded for
on three genes not genetically linked [16], a minimum of three missense mutations would have to
occur for the organism to become resistant.
To determine the potentiality of a dual-ligand inhibitor as an antibacterial agent, aminooxazole and moiramide B were connected via a hydrophobic carbon chain of varying lengths
[83]. In vitro kinetic assays revealed Compounds 11 and 12 (Figure 1.21) were able to inhibit
ACC with Ki’s in the nM range. Only compound 12, which contains a 7-carbon linker, was
shown to have antibacterial activity against most Gram-positive organisms and the efflux
compromised E. coli strain lacking the tolC outer-membrane channel, indicating that
modifications of this inhibitor could lead to a broad spectrum antibacterial agent. Furthermore,
compound 12 was found to have a low spontaneous resistant frequency, meaning the bacteria
affected are likely to become resistant to the dual ligand inhibitor at a slower rate. The inability
of compound 11 to exhibit antibacterial activity was due to the extremely hydrophobic 15-carbon
linker. This was overcome by co-incubating the cells with compound 11 and polymixin B
nonapeptide, a small molecule that increases the ability of hydrophobic molecules to pass
through the membrane, thereby enabling compound 11 to inhibit bacterial growth. Though
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neither compound was able to inhibit growth of all wild-type bacteria, this study set a precedent
for the further development of dual-ligand inhibitors of ACC.

11 (n)= 15
12 (n)= 7

Figure 1.21. Dual Ligand Inhibitors of Acetyl-CoA Carboxylase Containing Amino-oxazole,
Moiramide B, and a Hydrocarbon linker. 11 Hydrocarbon linker of 15 carbons. 12 Hydrocarbon
linker of 7 carbons.
1.6 Objectives and Rationale for Study
Fatty acid synthesis accounts for 94% of all ATP usage in membrane biogenesis [84],
thus ACC, which catalyzes the first committed step, must be tightly regulated. The purpose of
this dissertation is to examine two distinct types of regulation of ACC, both of which give insight
into the catalytic mechanism. In chapter 2, the mechanism of feedback inhibition by acyl-ACPs
was determined. In this study, it was discovered that ACC exhibits a time dependent, or
hysteretic, inhibition by the end product of FAS, palmitoyl-ACP. The hysteretic nature of ACC
acts as a “surge protector” to mitigate the effect of short-term fluctuating metabolites in the FAS
pathway. Furthermore, it was revealed that the inhibitory moiety of palmitoyl-ACP is the
cofactor pantothenic acid, which is covalently attached to ACP. The implications of this study
have far-reaching effects as pantothenic acid can be used as a scaffold to create novel
antibacterial agents for ACC. Chapter 3 describes a mechanism of regulation in which the N-
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terminal domain of BCCP stabilizes the carboxybiotin intermediate. Computational modeling
indicated that the N-terminal domain most likely lacks a stable three-dimensional structure, and
thus is an intrinsically disordered protein, which helped to explain two enigmas. First, it explains
why both the N-terminal domain and BCCP aggregate at high concentrations, and why any
attempt to glean information on the structure of the N-terminal domain has been for naught.
Second, it explains how the N-terminal domain can be involved in complex formation,
transcriptional regulation, and stabilization of the carboxybiotin intermediate, as the ability of the
N-terminal domain to fulfill multiple roles is characteristic of intrinsically disordered proteins.
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CHAPTER 2. ACETYL-COA CARBOXYLASE IN ESCHERICHIA COLI
EXHIBITS A PRONOUNCED HYSTERESIS WHEN INHIBITED BY
PALMITOYL-ACYL CARRIER PROTEIN1
2.1 Introduction
Fatty acid synthesis (FAS) is the most energy intensive metabolic pathway in bacteria [1].
The first committed and highly regulated step of FAS is catalyzed by acetyl-CoA carboxylase
(ACC). In most Gram-positive and Gram-negative bacteria, ACC is composed of three
components, biotin carboxylase (BC), the 2-subunit carboxyltransferase (CT) and biotin carboxyl
carrier protein (BCCP) [2]. These three components catalyze the carboxylation of acetyl-CoA to
form malonyl-CoA via two half-reactions (Scheme 2.1) [2].

Scheme 2.1.
In the first half-reaction, biotin carboxylase (BC) catalyzes the carboxylation of the
vitamin biotin which is covalently attached to BCCP. Carboxyltransferase (CT) then catalyzes
the transfer of the carboxyl group from biotin to acetyl-CoA, in the second half-reaction. Both
the BC and the CT enzymatic functions can be isolated and exhibit activity separately [2].
However, isolated BC can only catalyze the reaction using free biotin (i.e. there is no ATP
hydrolysis with biotinylated-BCCP as the substrate [3]). Moreover, the isolated CT function only

This article was published in Archives of Biochemistry and Biophysics, 636, Evans A., Ribble
W., Schexnaydre E., Waldrop GL. Acetyl-CoA Carboxylase in Escherichia coli exhibits a
pronounced hysteresis when Inhibited by Palmitoyl-acyl Carrier Protein, 100-109, Copyright
Elsevier (2017).
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catalyzes the reverse reaction when malonyl-CoA reacts with free biotin analog, biocytin [4]. In
contrast to the isolated components, the overall physiological reaction (Scheme 2.1) requires
formation of a complex of the three components and the presence of acetyl-CoA [3].
Acetyl-CoA carboxylase is subject to several levels of regulation in order to mediate the
flux of metabolites through FAS. One type of regulation is negative feedback inhibition on ACC
by acylated-ACPs [5]. The initial observation suggesting acylated-ACP exhibited negative
feedback inhibition came from overexpression of the gene coding for the protein thioesterase I
(TesA'), which hydrolyzes the bond between fatty acids and ACP. When the level of this enzyme
was increased, there was a concomitant increase in the flux of metabolites through fatty acid
synthesis [6]. It was subsequently determined that ACP esterified to fatty acids with 6–20 carbon
atoms inhibited the activity of both E. coli ACC [5], and plastidic ACC from Brassica napus [7].
Moreover, when some Gram-positive pathogens, such as Streptococcus agalactie, take up and
utilize host fatty acids, endogenous fatty acid synthesis is completely inhibited, which indicates
negative feedback inhibition of ACC [8]. Even though there is considerable evidence that
indicates acylated-ACP is responsible for feedback inhibition of ACC, the exact mechanism of
inhibition has not yet been determined, and therefore is the purpose of this study. In the original
study of negative feedback inhibition of ACC by acylated-ACP, Davis and Cronan [5] found that
ACP esterified with palmitic acid was the most effective acyl-ACP inhibitor of ACC. Therefore,
all of the studies described hereafter utilize palmitoyl-ACP (PACP). A significant, yet
unexpected, result of this study is that ACC formation exhibits a pronounced hysteresis. This
hysteretic phenomenon mitigates excessive fluctuations in metabolites, thereby giving the cell
more control over FAS.
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A detailed understanding of the inhibition of ACC by acylated-ACP benefits both the
biotechnology and pharmaceutical industries. The three-carbon product of ACC, malonyl-CoA,
is the precursor to the industrial chemical 3-hydroxypropionic acid, which is used to synthesize
polyacrylates [9,10]. Malonyl-CoA is also the building block for polyketides and flavonoids,
which can be used as pharmaceutical agents [11]. Unfortunately, the intracellular concentration
of malonyl-CoA is low (35 µM) [12,13], thereby limiting the production flux of the above
chemicals. Theoretically, increasing the intracellular level of malonyl-CoA by up-regulating the
activity of ACC should yield a significantly higher amount of product. Increased ACC activity,
however, leads to higher flux through FAS, causing an increase in the downstream product,
acylated-ACP, which in turn down regulates ACC. Therefore, to optimize malonyl-CoA
production this feedback inhibition must be circumvented. The first step to this end is a thorough
and detailed kinetic characterization of the mechanism of inhibition of E. coli ACC by acylatedACP.
2.2 Materials and Methods
2.2.1 Reagents
Amicon Ultracentrifugal Filters (molecular mass cut off of 3,000, 10,000, and 50,000
kDa) and Benzonase were from Millipore. M280 Streptavidin Dynabeads, and BL21 (DE3) E.
coli chemically competent cells were obtained from Invitrogen. The Bradford Protein assay
reagent, Opti-4CN substrate kit, and goat anti-mouse IgG (H+L)-HRP conjugates were
purchased from Novagen. Kanamycin, streptomycin, IPTG, D-Lactose and PINKstain Protein
Ladder were obtained from Gold Biotechnology. BioTrace PVDF Membranes were from PALL
Life Sciences. The monoclonal mouse anti-His Tag antibodies were purchased from Genscript.
Casamino acids were from Lab Scientific. The HiLoad 16/60 Superdex 200 prep-grade gel
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filtration column, HisTrap HP Ni Sepharose and HiTrap DEAE FF column were purchased from
GE Healthcare. Ni-NTA agarose was acquired from Qiagen. Protease inhibitor cocktail pellets
were from Roche. ACP synthase, NdeI, BamHI, DNA polymerase and Gibson Assembly master
mix were obtained from New England Biolabs. PfuII Ultra II hotstart PCR Master Mix was from
Stratagene. DNA Clean and Concentrator kit was obtained from Zymo research. The bacterial
strain E. coli 10G was from Lucigen. All other reagents were purchased from Sigma Aldrich.
2.2.2 Cloning, Expression, Purification, and Acylation of Acyl Carrier Protein.
The gene coding for acyl carrier protein (ACP) was cloned from E. coli BX_591, a
derivative of the plasmid BW25113 constructed at OPXBIO, and amplified using primers HL
234, and HL 235 (Table 2.1). The plasmid pET-28b was amplified separately with primers HL
233, and HL 222 (Table 2.1). PfuII Ultra II Hotstart PCR Master Mix was used in both PCR
reactions according to the manufacturer’s instructions. The PCR products were purified using
the DNA Clean & Concentrator kit. Plasmid pET-28-EcACP was constructed from the
amplification products using the Gibson Assembly Master Mix according to the manufacturer’s
instructions and the reaction mixture was transformed into E. coli 10G. The final plasmid
construct was confirmed by DNA sequencing, and transformed into BL21 (DE3) E. coli cells for
overexpression of the acyl carrier protein gene.
The gene for ACP was overexpressed by growing BL21(DE3) E. coli cells transformed
with pET-28-EcACP in two liters of Terrific Broth (TB) with 50 µg/mL kanamycin at 37°C to
mid log phase. Gene expression was induced by addition of 0.6 mM IPTG. The culture was
incubated with shaking for another 4.5 h at 37°C. Cells were then harvested by centrifugation
and cell pellets stored at -80°C.
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Frozen cell pellets were thawed and resuspended in 50 mM Tris pH 7.5 with 250
units/mL benzonase and protease inhibitor cocktail pellets. Cells were lysed by 2 passages
through a microfluidizer with addition of lysis buffer to wash out the fluid path. The lysate was
centrifuged and the supernatant decanted. Ammonium sulfate was slowly added to the
supernatant to a final concentration of 70% saturation. The precipitated protein was removed by
centrifugation and the resulting supernatant containing the ACP was dialyzed against 50 mM
Tris pH 7.5 and 5% glycerol.
Holo-ACP was generated by incubating the dialyzed ACP protein with 1 mM CoA and
200 nM ACP Synthase in 50 mM Tris, pH 8.0, 5 mM DTT, and 10 mM MgCl2 for 2 hours at
37°C. To make PACP, the ACP synthase reaction was subsequently diluted 2.5-fold in 50 mM
Tris buffer pH 8.0 with 500 µM palmitate, 10 mM MgSO4-, 10 mM ATP, 5 mM DTT, and 2.2
µM acyl-ACP synthetase. Diluted protein was then incubated for another 4 hours at 37°C to
produce palmitoyl-ACP.
The palmitoyl-ACP was purified by further dilution to reduce the conductivity and run
over a 1 mL HiTrap DEAE FF column equilibrated in 50 mM Tris, pH 7.6 and 25 mM NaCl.
After washing with the same buffer to reach a baseline, the column was washed with 10 column
volumes of 50 mM Tris, pH 7.6 with 50 mM NaCl. The protein was eluted using a linear 15
column-volume gradient from 50 mM to 190 mM NaCl. Fractions containing the palmitoylACP were pooled and the palmitoyl-ACP confirmed by mass spectrometry.
2.2.3 Cloning and Expression of Vibrio harveyi Acyl-ACP Synthetase
The gene coding for soluble acyl-ACP synthetase from Vibrio harveyi [14] was
synthesized using codons optimized for E. coli expression (GenScript) and sub-cloned for
expression as an N-terminal His-tagged protein in pET-28b. The protein coding sequence was
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amplified with primers HL 238 and HL 239 (Table 2.1), while the vector was amplified with
primers HL 221 and HL 222 (Table 2.1). The PCR reactions, cloning, and expression were
carried out as described above for the gene coding for ACP. Purification was accomplished
using nickel affinity chromatography.
Table 2.1. Primers for Plasmid Construction.
HL221

5’-ATGGCTGCCGCGCGG-3’

HL222

5’-GATCCGGCTGCTAACAAAG-3’

HL233

5’-GGTATATCTCCTTCTTAAAGTTAAACAAAAT-3’

HL234

5’-ATTTTGTTTAACTTTAAGAAGGAGATATACCATGAGCACTATC
GAAGAACG -3’

HL235

5’-CTTTGTTAGCAGCCGGATCTTACGCCTGGTGGCCG-3’

HL238

5’-CCGCGCGGCAGCCATATGAACCAATATGTCAACGACC-3’

HL239

5’-CTTTGTTAGCAGCCGGATCTTACAGATGCAGTTTACGCAG-3’

2.2.4 Expression and Purification of Acetyl-CoA Carboxylase and the Isolated Components
The plasmid pAEP3, constructed previously by Broussard et al. [3], containing the gene
for BCCP with a His-tag on the N-terminus was transformed into E. coli BL21 (DE3) cells. An
overnight of this strain was used to inoculate 0.5 L LB medium in a 2 L beveled flask containing
50 µg/mL of kanamycin. Flasks were shaken at 37°C until saturated. Expression was then
induced using 17.5 mM lactose and the culture shaken at room temperature for 3 hours, or
overnight, pelleted, and frozen at -20°C.
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The BCCP was purified using nickel affinity chromatography. The cell pellets were first
suspended in wash buffer (20 mM NaH2PO4, 500 mM NaCl, and 15 mM imidazole (pH 7.8)),
then lysed by sonication and passage through a French press. DNase was used to remove nucleic
acids. The cell lysate was centrifuged at 17,096g for 90 min at 4°C. Pellets were discarded, and
the supernatant was loaded onto a nickel affinity column that had been washed with 10 column
volumes of wash buffer. Protein was eluted into 5 mL fractions using a segmented gradient
starting with 8 column volumes of 0−10% elution buffer (20 mM NaH2PO4, 500 mM NaCl, and
250 mM imidazole (pH 7.8)), followed by 12 column volumes of 10−100% elution buffer, 8
column volumes of 100% elution buffer, followed by 5 column volumes of NPI-500 (20 mM
NaH2PO4, 500 mM imidazole, 500 mM NaCl). Fractions containing BCCP were concentrated
using Amicon Centrifugal Filters and further purified over a size exclusion column in a buffer
containing 10 mM HEPES and 150 mM KCl (pH 7.8). Fractions containing the pure protein
were concentrated using Amicon centrifugal filters, aliquoted, and stored at -80°C.
Biotin carboxylase with a His-tag on the N-terminus was purified according to Blanchard
et al [15]. Carboxyltransferase with a His-tag on the N-terminus of the α-subunit was purified
according to Blanchard & Waldrop [4]. The multiprotein ACC complex with a His-tag on the Nterminus of BCCP was purified according to Broussard et al [3].
2.2.5 Pull Down Assays
Pull downs targeting biotinylated BCCP used Invitrogen M-280 Streptavidin Dynabeads
(10mg/ml). The beads (100µl) were washed 3 times with washing buffer (PBS (pH 7.4)) and
resuspended in the same buffer. The magnetic Streptavidin Dynabeads were separated out of
solution with a neodymium magnet and were resuspended in 50 µl of the following solution: 10
mM HEPES (pH 7.8) and 150 mM KCl containing 55.5 µM biotinylated BCCP. The suspension
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was incubated on a rotary incubator for one hour at RT. The beads were separated from the
solution using the neodymium magnet, and the supernatant was removed. The biotinylatedBCCP Streptavidin Dynabeads were then washed twice with washing buffer and resuspended in
a target solution of 1.67 mM AMPPNP, 0.7 µM CT, 0.94 µM BC, 22.2 mM MgCl2, and 22.2
mM potassium bicarbonate in 111.1 mM HEPES pH 7.8. PACP was either omitted from the
target solution (control), included with the target solution (0 min), or introduced 5 minutes after
the target solution incubation began (5min). Each of these three solutions were incubated for a
total of 45 minutes. The beads were washed three times with PBS before they were resuspended
in 10 µls of Laemmli 2X sample buffer plus 20µls of PBS-0.1% Tween-20 and incubated at 80°C
for 15 minutes. The products of the pull-downs were then stored at -20°C for Western blot
analysis.
2.2.6 Western Blot Analysis
The pull-down samples were run on a 10% SDS-PAGE gel, and transferred to a PVDF
membrane using a Bio-Rad Trans Turbo Blot system as published previously [3]. The PVDF
membrane was incubated in blocking solution for one hour at room temperature with light
shaking. The membrane was then incubated in a primary antibody solution containing a 1:1000
dilution of GeneScript monoclonal mouse anti-His tag antibody in 0.1%Tween-20 PBS for one
hour at RT with light shaking. Thereafter, the membrane was washed three times for 10 minutes
each with wash buffer. The membrane was then incubated in anti-mouse secondary antibody
solution for one hour at RT with light shaking, followed by a 10-minute incubation in wash
buffer. The membrane was then rinsed twice for 2 minutes with distilled water before adding the
chromogenic agent. Once bands were visible, the membrane was rinsed twice for 2 minutes with

55

distilled water before it was allowed to dry. All buffers not defined, as well as the secondary
antibody for Western development were part of Life Technologies’ Western Breeze kit.
2.2.7 Enzymatic Assays
The activity of the acetyl-CoA carboxylase complex [3], biotin carboxylase [15] and
carboxyltransferase [4] were determined as previously described. All reactions were initiated by
addition of enzyme to a 1 cm path length quartz cuvette at RT. When measuring activity of in
vitro ACC, the reaction was initiated by adding 20 µl of the following solution: 8 µM BC, 6 µM
CT, and 50 µM BCCP and, where indicated, 50 µM PACP in 10 mM HEPES (pH 7.8) and 150
mM KCl. Unless otherwise noted, BC, CT, and BCCP were mixed and incubated for 5 minutes
prior to the addition of PACP. Spectrophotometric data were collected using a Cary 60 (Agilent)
spectrophotometer interfaced with a personal computer with a data acquisition program.
Velocities were reported as µmol of product per minute per milligram of enzyme. Mass of
PACP was omitted from velocity calculations.
2.2.8 Kinetic Analysis
Data were analyzed by nonlinear regression using the computer programs of either
Cleland [16] or Enzfitter. Data describing competitive inhibition were fitted to equation 1 where
v is the initial velocity, V is the maximal velocity, A is the substrate concentration, Km is the
Michaelis constant, I is the concentration of the inhibitor and Kis is the slope inhibition constant.
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Data describing non-competitive inhibition were fitted to equation 2 where v is the initial
velocity, V is the maximal velocity, A is the substrate concentration, Km is the Michaelis constant,
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I is the concentration of the inhibitor and Kis is the slope inhibition constant, and Kii is the
intercept inhibition constant.
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Multiple inhibition data were fitted to equation 3, where v is the initial velocity, V is the maximal
velocity, KL and KJ are the apparent dissociation constants for the two inhibitors (L and J) and α
is a measure of the degree of interaction of the two inhibitors [17].
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2.3 Results
2.3.1 Effect of Palmitoyl-ACP on ACC Activity
The effect of PACP on the activity of ACC and the purified BC and CT enzymatic halfreactions is shown in Figure 2.1. There was no inhibition of CT or BC activity by PACP
confirming the findings of Davis and Cronan [5] (Figure 2.1, Blue and Green, respectively).
Davis and Cronan, however, reported acyl-ACP inhibits ACC [5], but we did not observe
inhibition of ACC isolated from cells as a complex (Figure 2.1, Yellow). A possible reason for
this discrepancy may be in the preparation of the enzyme, therefore, the complex was formed in
vitro, and tested for inhibition by PACP. When the BC, CT, and BCCP components were mixed
simultaneously with PACP, incubated for 5 minutes, then activity measured, there was a 15%
decrease in activity compared to the control (Figure 2.1, Pink). When the components of ACC
were incubated together for five minutes prior to the addition of PACP, however, there was a
more significant decrease (55%) in activity compared to the control, (Figure 2.1, Black), which
was consistent with the findings of Davis and Cronan [5]. The observation of hysteresis
prompted a further investigation into the time dependence of PACP inhibition of ACC.
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Figure 2.1. Enzymatic Activity in the Presence and Absence of Palmitoyl-Acyl Carrier Protein
(PACP). The activity of BC, CT, or ACC reaction in the absence of PACP was used as the
control, and set at 100%. A (+) symbol below the bar indicates the presence of either 8 µM BC,
6 µM CT, 50 µM BCCP, 0.094 mg ACC, 50 µM PACP or a combination of the aforementioned
proteins. The row labeled incubation indicates how long (in minutes) the components were
incubated together before the addition of 50 µM PACP. N/A stands for not applicable, as in there
was no incubation period before measuring activity. Each measurement represents the average
of three replicates ± the standard deviation.
The time dependence for the inhibition of ACC by PACP is shown in Figure 2.2. In this
study, the purified components of ACC were mixed, incubated for a defined period of time (xaxis), PACP was added, and activity was immediately measured. At 0 and 2.5 minutes, there
was 15% and 20% inhibition of activity, respectively. The most significant inhibition was
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observed after a 5-minute incubation period, with a 55% decrease in ACC activity. In contrast,
after 10 minutes, there was only a 5% decrease in activity, and after 20 minutes there was no
inhibition. These results show that the method by which the multiprotein complex of ACC is
formed is critical for detecting inhibition by PACP. In other words, once ACC formed in vitro
had incubated for 10 min or longer, the enzyme was no longer susceptible to significant
inhibition by PACP, similar to ACC formed in vivo. These results indicate that in the absence of
acetyl-CoA, ACC formation exhibits a pronounced hysteresis with respect to inhibition by
PACP. The inability of PACP to inhibit ACC after 20 min suggests that PACP may inhibit ACC
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Figure 2.2. Time Dependence of Inhibition of Palmitoyl-Acyl Carrier Protein (PACP) on ACC.
The initial velocity of ACC in the absence of PACP was set at 100% and used as the control. 8
µM BC, 6 µM CT, and 50 µM BCCP, were mixed and incubated for a defined period of time (xaxis) before addition of 50 µM PACP. Each measurement represents the average of three
replicates ± the standard deviation.
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2.3.2 Effect of PACP on ACC Complex Formation
A pull-down assay was used to determine if PACP inhibited formation of the
multiprotein complex of ACC (Figure 2.3). Briefly, biotinylated BCCP was immobilized on
Streptavidin Dynabeads and used as a target protein to bind the remaining components of ACC
(BC and/or CT). A control reaction in which PACP was omitted is shown in Lane 1. In Lanes 2
and 3, PACP was either added simultaneously with the components (Lane 2), or introduced after
a 5-minute incubation of the multiprotein complex (Lane 3). The conditions in Lane 2 are
equivalent to Figure 2.1, Pink, while Lane 3 represents the same conditions seen in Figure 2.1,
Black. All three components of ACC contain a His-tag, therefore, an antibody specific for a Histag was used to detect the proteins on a Western blot. If PACP inhibits complex formation, then
BCCP will be detected, but the bands representing BC and/or CT would be significantly lighter,
or absent. In contrast, if PACP does not inhibit complex formation, then BC, CT, and BCCP will
all be detected on the Western blot. The results show that there is no significant difference in the
intensity of the bands for BC, or CT (Lanes 1-3) indicating that PACP does not inhibit formation
of the complex. It is important to note that in a subsequent pull down assay (data not shown) a
band for PACP was visible, indicating that PACP does bind to the multiprotein complex, but
does not inhibit complex formation. Additionally, PACP was not shown in presented data as its
molecular weight (~ 9 Kd) was too low. Given that PACP does not appear to inhibit ACC
activity by abrogating multiprotein complex formation, the mechanism of inhibition was
characterized kinetically.
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Figure 2.3. Pull-Down Assays to Determine the Effect of Palmitoyl-Acyl Carrier Protein
(PACP) on the Complex Formation of ACC. Lanes 1-3 represent Streptavidin Dynabeads bound
to biotinylated BCCP in the presence of BC and CT. Lanes 2 and 3 also included PACP
introduced at 0 min of incubation (lane 2) and 5 min (lane 3), respectively. Lanes 4-6 are purified
BCCP, BC, and CT, respectively. The presence of the proteins was detected using an anti-His
tag antibody because each protein has a His-tag on the N-terminus.
2.3.3 Kinetics of PACP Inhibition
Inhibition analyses were conducted to determine the mechanism of inhibition of PACP on
ACC. A noncompetitive inhibition pattern was observed when ATP, a substrate for BC, was
varied at different fixed levels of PACP (Figure 2.4 A). In contrast, PACP exhibited competitive
inhibition when acetyl-CoA, a substrate for CT, was varied at different fixed levels of PACP
(Figure 2.4 B). When the data in Figure 2.4 B were fitted to the equation for competitive
inhibition (equation 1) an inhibition constant (Kis) of 88.0 ± 5.8 µM was calculated with a Km of
0.44 ± 0.01 mM and a Vmax of 0.34 ± 0.01 µmol/min/mg.
Since PACP does not inhibit either of the individual enzymatic half-reactions (BC or
CT), PACP was expected to act as an allosteric inhibitor of ACC and exhibit either
noncompetitive, or uncompetitive inhibition, as was the case versus ATP. The competitive
inhibition pattern versus acetyl-CoA suggests that an alternative mechanism of inhibition may be
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partial competitive inhibition where the inhibitor and substrate bind at different sites. The
turnover of the ES and EIS complexes would occur at the same rate, while the affinity of
substrate for E and EI is affected. It is important to note that Davis and Cronan found that
activity of ACC was never completely abolished by acyl-ACP [5], which is consistent with a
partial competitive inhibition mechanism.
To confirm PACP binds allosterically to ACC a multiple inhibition analysis was
conducted. Briefly, multiple inhibition studies are carried out by determining the initial velocity
at increasing concentrations of one inhibitor while the second inhibitor is held constant [17]. The
substrate concentrations are held constant at sub-saturating levels, which allows both inhibitors
to bind to the enzyme. In the case of ACC, the initial velocity was measured as a function of
increasing amounts of malonyl-CoA, a product inhibitor of ACC, at fixed increasing levels of
PACP (Figure 2.4 C), while the substrates ATP and acetyl-CoA were held at sub-saturating
levels. When the data were plotted as a Dixon plot an intersecting pattern was observed,
indicating that malonyl-CoA and PACP can bind simultaneously. In other words, the binding
sites for PACP and malonyl-CoA are topologically distinct. These results are consistent with
Figure 2.1, Blue, and confirm that PACP does not bind in the active site of CT, but inhibits ACC
allosterically. This result is also consistent with a mechanism of partial competitive inhibition.
Furthermore, when the data in Figure 2.4 C were fitted to Equation 3, an α value of 1.5 was
calculated. The α value in equation 3 is an indication of the interaction between the two
inhibitors, where a value greater than 1 signifies an antagonistic effect. An α value of 1 would
indicate no interaction between the inhibitors, while an α value less than 1 would indicate
synergism in the binding of the inhibitors [17]. Thus, the fact that PACP and malonyl-CoA
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interact antagonistically suggests that PACP interferes with the second half-reaction which is
catalyzed by CT.
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Figure 2.4. Inhibition of ACC. A. Inhibition by palmitoyl-acyl carrier protein (PACP) at 0 µM
(u), 30 µM (n), and 50 µM (l) while varying ATP and holding acetyl-CoA constant at 0.5
mM. Points represent observed velocities, while lines represent best fit of the data to equation 2.
B. Inhibition by PACP at 0 µM (u), 30 µM (n), and 50 µM (l) while varying acetyl-CoA and
holding ATP constant at 0.2 mM. Points represent observed velocities, while lines represent best
fit of the data to equation 1. C. Multiple inhibition of ACC in the presence of PACP. MalonylCoA was used as a product inhibitor, and was varied at fixed levels of PACP at 0 µM (u), 50
µM (n), and 70 µM (l). The points represent observed velocities, while the lines represent best
fit of the data to equation 3.
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Given that ACC forms a multiprotein complex that is required for catalysis [3], we
investigated the possibility that PACP may hinder the communication between the two active
sites of BC and CT. For this study, the stable complex of CT-BCCP was prepared in vitro in the
same manner as in vitro ACC as previously published [3]. The concentration of the BC
component was varied in the presence and absence of PACP, while the substrates ATP and
acetyl-CoA were held at sub-saturating levels. As shown in Figure 2.5 A, a noncompetitive
inhibition pattern was observed, which is congruous with the fact that PACP is noncompetitive
with respect to ATP (Figure 2.4 A). In contrast, when the purified BC-BCCP complex was held
constant, and the concentration of the CT was varied at different fixed levels of PACP, a
competitive inhibition pattern was observed (Figure 2.5 B). This is consistent with PACP acting
as a competitive inhibitor with respect to acetyl-CoA (Figure 2.4 B). These results suggest that
PACP hinders the productive binding of CT to the BC-BCCP complex.
2.3.4 Structure Activity Analysis of PACP Inhibition on ACC
A structure function analysis was carried out in order to determine which moiety of
PACP is responsible for the inhibitory effect on ACC. Palmitoyl-ACP is composed of three
distinct chemical components: (1) the acyl carrier protein (apo-ACP), (2) a pantothenic acid arm
and (3) palmitic acid. These three components, plus ACP modified with the pantothenic acid
arm (holo-ACP) were tested for their ability to inhibit ACC activity. For these studies, the
purified components of ACC were mixed in the presence and absence of one of these four
potential inhibitors. The ACC components BC, CT, and BCCP were incubated together for five
minutes prior to the addition of the inhibitor as described in Figure 2.1. As shown in Figure 2.6
A, apo-ACP (Pink), holo-ACP (Green) and palmitic acid (Yellow) had no inhibitory effect. The
absence of inhibition by holo-ACP is consistent with Davis and Cronan who reported that holo-
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ACP did not inhibit ACC [5]. Surprisingly, pantothenic acid (Figure 2.6 A, Black) significantly
inhibited ACC (58%), suggesting that pantothenic acid is the moiety of PACP that is responsible
for inhibition of ACC.
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Figure 2.5. Inhibition by Palmitoyl-Acyl Carrier Protein (PACP) on ACC Component
Interaction. A. CT-BCCP complex was held constant while varying BC at 0 µM (u), 30 µM
(n), and 50 µM (l) PACP. Points represent observed velocities, while lines represent best fit of
the data to equation 2. B. BC-BCCP complex was held constant while varying CT at 0 µM (u),
50 µM (n), and 60 µM (l) PACP. Points represent observed velocities, while lines represent
best fit of the data to equation 1.
To determine if ACC formation exhibits hysteresis in the presence of pantothenic acid,
the time dependence of inhibition was examined (Figure 2.6 B). The purified components of
ACC (BC, BCCP, and CT) were mixed and incubated for 0, 5, or 20 minutes, pantothenic acid
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was added, and activity was measured. At 0, 5, and 20 minutes pantothenic acid exhibited 23%,
58%, and 3% inhibition compared to the control, respectively. Thus, pantothenic acid exhibited
a time-dependent inhibition pattern similar to that of PACP (Figure 2.2).
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Figure 2.6. A. Inhibition of ACC by the Chemical Components of Palmitoyl-Acyl Carrier
Protein (PACP). The activity of ACC in the absence of inhibitor was used as the control, and set
at 100%. Each reaction contained 8 µM BC, 6 µM CT, and 50 µM BCCP, and 50 µM of the
chemical component indicated, which was added after the components of ACC were incubated
together for 5 minutes. Each measurement represents the average of three replicates ± the
standard deviation. B. Time dependence of inhibition of pantothenic acid on ACC. The initial
velocity of ACC in the absence of pantothenic acid was set at 100% and used as the control. The
components of ACC were mixed and incubated for a defined period of time (x-axis) before
addition of pantothenic acid. Each measurement represents the average of three replicates ± the
standard deviation.
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Interestingly, pantothenic acid still inhibited after 20 minutes, unlike PACP, indicating
that pantothenic acid may be a better inhibitor than PACP. Therefore, both the type and degree
of inhibition of ACC by pantothenic acid was examined. A noncompetitive inhibition pattern
was observed when ATP was varied at different fixed levels of pantothenic acid (data not
shown), while a competitive inhibition pattern was observed, when acetyl-CoA was varied at
different fixed levels of pantothenic acid (Figure 2.7 A). These inhibition patterns for
pantothenic acid were in agreement with the inhibition patterns exhibited by PACP (Figures 2.4
A and 2.4 B). When the data in Figure 2.7 A were fitted to equation (1) an inhibition constant of
43.9 ± 6.3 µM was calculated, with a Km of 0.26 ± 0.02 mM and a Vmax of 0.065 ± 0.002
µmol/min/mg, confirming that pantothenic acid is a more potent inhibitor of ACC than PACP.
To determine if pantothenic acid binds to ACC allosterically, analogous to PACP, a
multiple inhibition analysis was performed. The initial velocity of ACC was measured by
varying the product inhibitor, malonyl-CoA, at different fixed levels of pantothenic acid, while
ATP and acetyl-CoA were held constant at sub-saturating levels. When the data were plotted as a
Dixon plot an intersecting pattern was observed (Figure 2.7 B), indicating that malonyl-CoA and
pantothenic acid can bind simultaneously. These results are consistent with the multiple
inhibition analysis for PACP and confirm that pantothenic acid also does not bind in the active
site of CT, but inhibits allosterically. When the data in Figure 2.7 B were fitted to Equation 3, an
α value of 2.4 was calculated, indicating a larger antagonistic effect than observed with PACP.
These results suggest that pantothenic acid is both the inhibitory moiety of PACP as well as a
more potent inhibitor of ACC.
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Figure 2.7. A. Inhibition of ACC. Inhibition by pantothenic acid at 0 µM (u), 30 µM (n), and
50 µM (l) while varying acetyl-CoA and holding ATP constant at 0.2 mM. Points represent
observed velocities, while lines represent best fit of the data to equation 1. B. Multiple inhibition
of ACC in the presence of pantothenic acid and malonyl-CoA. Malonyl-CoA was used as a
product inhibitor, and varied at fixed levels of pantothenic acid at 0 µM (n), 50 µM (u), and 70
µM (l). The points represent observed velocities, while the lines represent best fit of the data to
equation 3.
2.4 Discussion
2.4.1 Hysteresis and Enzymology
The term hysteresis was first defined in physics to describe a physical phenomenon in
which a lag, or delay is observed. In 1970 Carl Frieden introduced this term to enzymology after
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he discerned that some regulatory enzymes exhibit a delay in activity in response to a change in
metabolite concentration [18]. For example, glycogen phosphorylase exhibits a hysteretic
interconversion between an inactive tetramer and an active dimer in response to glycogen [18,
19]. Prior to Frieden’s study, researchers failed to note the correlation between time dependent
enzymes and metabolic regulation. However, Frieden determined hysteresis was not just a
random phenomenon, but a way for the cell to exercise increased control over metabolite
production [20, 21].
2.4.2 Hysteresis of Acetyl-CoA Carboxylase
We propose that the hysteretic behavior of ACC may play a key role in the regulation of
the flux through FAS. Specifically, when large quantities of the end product PACP accumulate
quickly, and are quickly processed, the hysteresis prevents an instantaneous down regulation of
fatty acid synthesis. Thus, fatty acid production can continue at its normal rate, obviating
dramatic oscillations in the levels of FAS intermediates.
The significance of limiting these oscillations becomes apparent when considering other
metabolic pathways in which FAS intermediates play a key role. For example, FAS also supplies
the building blocks for the synthesis of lipoic acid and biotin, of which the initial substrates are
octanoic acid and malonyl-CoA, respectively. Due to the hysteresis, flux through the lipoic acid
and biotin synthetic pathways would remain unaffected by sudden changes in the level of acylACP.
Acetyl-CoA carboxylase is not the only enzyme in FAS inhibited by acyl-ACP. In fact,
FabH, which catalyzes the condensation of acetyl-CoA with the growing acyl chain, and FabI,
which catalyzes the reduction of the intermediate double bond in the acyl chain are also inhibited
by acyl-ACP [22]. Interestingly, FabH and FabI have not been found to exhibit hysteresis in
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response to acyl-ACPs. Activity for both enzymes was measured using fixed-time assays with a
single time point, however, which may have masked any hysteretic behavior [22]. More likely,
as acyl-ACPs are a substrate for FabH and a product of FabI, the mechanism of inhibition is
either substrate or product inhibition, respectively, and most likely would not exhibit hysteresis.
This differs significantly from the inhibition of ACC by PACP, where the data strongly suggest
that inhibition is hysteretic, as well as allosteric.
2.4.3 Mechanism of Inhibition
The inhibition of ACC by PACP clearly occurs via an allosteric mechanism. Although
inhibition studies suggested PACP and acetyl-CoA compete for the same binding site, more
rigorous studies (multiple inhibition, Figure 2.4 C) demonstrated that PACP and acetyl-CoA bind
in separate locations in an antagonistic manner. This is consistent with the observation that
PACP interferes with the productive binding of CT with the BC-BCCP complex (Figure 2.5 B).
A possible model to explain this phenomenon is shown in Figure 2.8. Figure 2.8
illustrates the relationship between the change in conformation of ACC in the absence of
substrate, and the binding of PACP. The data suggest there is a finite period of time in which
PACP can inhibit ACC, indicating that ACC undergoes a slow isomerization beginning when
CT, BCCP, and BC are first combined. This initial interaction is shown as Eo. A slow (5minute) isomerization occurs to give E*, creating a binding site for PACP (I) forming EI*. After
this finite period passes (10 minutes or more), or if there is a large concentration of acetyl-CoA,
ACC assumes a conformation (E′) that eliminates the binding site for PACP, thereby preventing
the inhibition of ACC by PACP. The E′ complex is analogous to ACC purified from cells after
forming in vivo.
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This mechanism of allosteric inhibition of ACC by PACP can be compared to the
inhibition of protein kinase Bα (PKBα) by AKT inhibitor VIII [23]. Protein kinase Bα can be
found in either an active or inactive conformation. The inactive conformation creates a binding
site for AKT inhibitor VIII which, upon binding, locks the enzyme into an inactive state.
Conversely, in the active conformation the AKT inhibitor VIII binding site is not present
resulting in no inhibition. Similarly, ACC may create a binding site for PACP that is only present
whilst ACC is isomerizing.

Figure 2.8. Model Depicting the Relationship Between the Change in Conformation of ACC in
the Absence of Substrate, and the Binding of PACP. Eo represents the conformation of the ACC
components immediately after mixing. E* represents the conformation of the ACC components
after a 5-minute incubation period, in which the inhibitor may bind to form EI*. E ′ represents
the conformation of ACC when the components have incubated for 10 minutes or more.
The inhibition of ACC by PACP provides insight into the state of ACC in vivo. Based on
the data presented here, it follows that in order for PACP to act as a metabolic regulator, the
formation of the ACC complex must be in flux. For example, if the ACC multiprotein complex is
continually forming, and dissociating, then PACP would continually have a target for inhibition.
The half-life of ACC has not been reported, however, proteins with a regulatory role generally
have short half-lives. Since ACC catalyzes the rate-determining and regulated step in fatty acid
synthesis in bacteria [24], the turnover of acetyl-CoA carboxylase is likely to occur regularly
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presenting a continuous target for inhibition by PACP. Further evidence that the results reported
here are relevant in vivo are the endogenous level of acetyl-CoA in E. coli in the growth phase
(which is when palmitoyl-ACP would be produced) is 0.6 mM [13] This level of acetyl-CoA is
in the mid-range of concentrations used in Figure 2.4, showing that acetyl-CoA reverses the
inhibition by PACP. Moreover, the inhibition constant for PACP (~88 µM) is close to the
endogenous level of ACP (~ 100 µM) [25]. Since neither apo-ACP nor holo-ACP inhibit ACC,
this means that ACC (and by inference FAS) would only be inhibited when the majority of the
ACP has been acylated. If the inhibition constant for PACP were lower (i.e. palmitoyl-ACP
bound to ACC more tightly) this would mean only a small amount of palmitoyl-ACP would be
required to inhibit ACC, which would be deleterious to cell growth. Thus, the kinetic results
observed in vitro are consistent with the in vivo levels of substrate and inhibitor.
2.4.4 Structure-Activity Relationships
The structure-activity studies clearly indicate that the pantothenic acid moiety of PACP is
responsible for the inhibition of ACC, which explains why apo-ACP (ACP without pantothenic
acid) has no effect on ACC. What is not clear, however, is why acyl-ACP and pantothenic acid
inhibit ACC, but holo-ACP, which also contains the pantothenic acid component, does not. A
possible mechanism for inhibition can be gleaned by comparing the three-dimensional structures
of ACPs bound to LpxD acyl transferase [26] versus unbound acyl-ACP [26]. LpxD is an
enzyme that transfers the acyl group from acyl-ACP to the amino group of UDP-3-O(hydroxytetradecanoyl) glucosamine during Lipid A synthesis in Gram-negative bacteria. The
crystal structure of unbound acyl-ACP from E. coli (Figure 2.9 A) shows the four helices create a
hydrophobic pocket (Pink) that surrounds the growing acyl chain (Black) with the pantothenic
acid arm (Yellow) close to the protein [26]. In contrast, the crystal structure of LpxD bound to
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acyl-ACP (Figure 2.9 B), shows that the acyl chain (Black) is no longer in the hydrophobic
pocket of ACP (Pink) but is inserted into the active site of the enzyme (Light Blue), causing the
pantothenic arm (Yellow) to become straight [26]. This translocation exposes pantothenic acid to
interactions with the catalytic residues of LpxD, shown in Red. Conversely, the crystal structure
of LpxD bound to holo-ACP (Figure 2.9 C) shows the pantothenic arm (Yellow) is not extended
towards the catalytic residues (Red) of the enzyme (Light Blue), but is curled up towards ACP
(Pink), preventing or minimizing the interactions of the catalytic residues (Red) of LpxD (Light
Blue) with the pantothenic arm [26]. Consistent with this proposed mechanism is that in
unbound holo-ACP the position of pantothenic acid is highly variable [27]. Therefore, the
interaction of acyl-ACP and holo-ACP with ACC may be similar to that of LpxD, which may
explain why holo-ACP is unable to inhibit ACC.
2.5 Conclusions
This report shows two major findings. First, the flux through FAS is more tightly
regulated than previously reported. Specifically, the marked hysteresis of ACC negates
deleterious effects of oscillations in FAS metabolites when inhibited by PACP. Second, the
novel finding that pantothenic acid is the moiety of PACP that inhibits ACC with a micromolar
Kis. Thus, pantothenic acid can lead to a scaffold for developing allosteric inhibitors of the
enzyme which could serve as new antibacterial agents. Both catalytic functions of ACC, biotin
carboxylase and carboxyltransferase, have been validated as targets for antibacterial
development [28]. Antibacterial agents, to date, targeting biotin carboxylase and
carboxyltransferase bind in the active site. In contrast, the allosteric inhibition of ACC by
pantothenic acid suggests an unforeseen binding site in the multiprotein complex that can be
targeted to design inhibitors with antibacterial activity.
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A.

B.

C.

Figure 2.9. Three-Dimensional Structures of Various Forms of ACP. A. Three-dimensional
structure of unbound acyl-ACP (ACP is pink, pantothenic acid is yellow, acyl chain is black)
(PDB: 1lOI). B. Three-dimensional structure of acyl-ACP (ACP is pink, pantothenic acid arm is
yellow, acyl chain is black, catalytic residues are red), in complex with LpxD (light blue) (PDB:
4IHF). C. Three-dimensional structure of holo-ACP (ACP is pink, pantothenic acid arm is
yellow, catalytic residues are red) in complex with LpxD (light blue) (PDB: 4IHH).
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CHAPTER 3. THE ROLE OF THE N-TERMINAL DOMAIN OF BIOTIN
CARBOXYL CARRIER PROTEIN IN CATALYSIS BY BACTERIAL
ACETYL-COA CARBOXYLASE
3.1 Introduction
Acetyl-CoA carboxylase (ACC) catalyzes the first committed and regulated step of fatty
acid synthesis in all animals, plants, and bacteria [1]. The reaction catalyzed by ACC occurs via
two half-reactions (Scheme 3.1).

Scheme 3.1.
In the first half-reaction, the vitamin biotin, which is covalently linked to the biotin carboxyl
carrier protein (BCCP), undergoes an ATP-dependent carboxylation catalyzed by biotin
carboxylase (BC). In the second half-reaction, the carboxyl group is transferred from biotin to
acetyl-CoA by carboxyltransferase (CT) forming malonyl-CoA.
Though the function of ACC in all animals, plants, and bacteria is the same, the structures
of ACC differ greatly between organisms. In bacteria, catalysis by ACC requires formation of a
macromolecular complex composed of three separate subunits (BC, CT, and BCCP) [2], though
BC and CT retain their activity when purified separately [1]. Alternatively, in most eukaryotes
ACC is a single polypeptide chain where the three proteins (BC, CT and BCCP) are organized
into domains [3]. Though the BC and CT subunits in bacterial ACC mimic the BC and CT
domains in eukaryotes [4, 5, 6, 7], the BCCP subunit in bacteria differs significantly from the
BCCP domain in eukaryotes.
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Bacterial BCCP contains two domains [1] connected by a proline/alanine rich linker [8].
These domains in E. coli are referred to as the N-terminal domain (NTD), composed of residues
1-71, and the C-terminal domain, which will be referred to hereafter as the biotinyl domain (BD),
and is composed of residues 77-156. While both NTD and the BD have been shown to affect
catalysis of ACC [2, 9], only the role of the BD in catalysis of ACC has been determined. In this
report, the role of NTD in the catalytic mechanism of ACC has been investigated.
3.2 Materials and Methods
3.2.1 Reagents
Amicon Ultracentrifugal Filters (molecular mass cut off of 3,000, 10,000 and 50,000
kDa) were from Millipore. Beads with a His-tag covalently linked were obtained from
Invitrogen. The Bradford Protein assay reagent, the plasmids pET28b+ and pCDF-Duet were
purchased from Novagen. Kanamycin, ampicillin, streptomycin, isopropyl β-D-1thiogalactopyranoside (IPTG), D-Lactose and PINKstain Protein Ladder were obtained from
Gold Biotechnology. Casamino acids were from Lab Scientific. NdeI, HindIII, and BamHI were
from New England BioLabs. The HiLoad 16/60 Superdex 200 prep-grade gel filtration column
and HisTrap HP Ni Sepharose was purchased from GE Healthcare. Ni-NTA agarose was
acquired from Qiagen. All other reagents were purchased from Sigma Aldrich.
3.2.2 Cloning of the Biotinyl Domain of Biotin Carboxyl Carrier Protein
The gene coding for the BD (the last 87 residues of BCCP) was generated by PCR using
primers BCCP875 and 2AEPBCCP2 (Table 3.1) and the plasmid pYML11 [2], which contains
the gene for full-length BCCP. The PCR product was inserted into pET28b+ between NdeI and
BamHI to create pEMP3.
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Table 3.1. Primers for Plasmid Construction.
Protein
Primer Name
THNS
THNS
BD
BD/NTD

THNSForward
THNSReverse
BCCP875
2AEPBCCP2

NTD

2AEPBCCP1

Primer
5’-3’
CTTCTTGGATCCGATGACCACTCTGTGCCGC
CTTCTTAAGCTTTCATTAATCGGCGGTCTG
CTTCTTCATATGGAAGCGGCCAGCAGCAGCG
CTTCTTGGATCCACCTCCTTACTCGATGACGACCAG
CGCGCTC
CTTCTTCATATGGATATTCGTAAGATTAAAAAA

3.2.3 Cloning of the N-terminal domain of Biotin Carboxyl Carrier Protein
The gene coding for NTD (the first 77 residues of BCCP) was generated by PCR using
primers 2AEPBCCP1 and 2AEPBCCP2 (Table 3.1) and the plasmid pYML11 [2] which
contains the gene for full-length BCCP. The PCR product was then inserted into pET28b+
between NdeI and BamHI to create pAEP5.
3.2.4 Cloning of 1,3,6,8-Tetrahydroxynapthalene Synthase (THNS)
The plasmid containing the gene coding for THNS was a gift from OPX Biotechnologies,
Boulder, CO. The gene was amplified by PCR using primers THNSForward and THNSReverse
(Table 3.1). The PCR product was inserted into pCDFDuet-1 between BamHI and HindIII to
create pAER1.
3.2.5 Purification of the N- and C-Terminal Domains of Biotin Carboxyl Carrier Protein
The plasmid coding for the BD (pEMP3) was transformed into E. coli BL21 (DE3). An
overnight of that strain was then used to inoculate 0.5 L LB medium in a 2 L beveled flask,
which contained 50 µg kanamycin. Cultures were incubated at 37° C until an OD600 of 0.6. The
cultures were cooled to room temperature and expression induced using 250 µM IPTG. The
cultures were incubated with shaking for an additional 3 hours. The cells were pelleted, and then
frozen at -20° C.
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The cell pellets were thawed and resuspended in buffer (20 mM NaH2PO4, 500 mM
NaCl, and 15 mM imidazole (pH 7.8)), then sonicated and passed through a French press to lyse
the cells. DNase was used to remove nucleic acids and the cell lysate was centrifuged at 17,096g
for 60 min at 4° C, the pellets were discarded. The supernatant was loaded onto a nickel affinity
column that had been washed with 10 column volumes of buffer (20 mM NaH2PO4, 500 mM
NaCl, and 15 mM imidazole (pH 7.8)). Protein was eluted into 5 mL fractions using a segmented
gradient starting with 8 column volumes of 0−10% elution buffer (20 mM NaH2PO4, 500 mM
NaCl, and 250 mM imidazole (pH 7.8)), then by 12 column volumes of 10−100% elution buffer,
8 column volumes of 100% elution buffer, followed by 5 column volumes of NPI-500 (20 mM
NaH2PO4, 500 mM imidazole, 500 mM NaCl). Fractions containing the BD were concentrated
using Amicon Centrifugal Filters and purified over a size exclusion column in a buffer
containing 10 mM HEPES and 150 mM KCl (pH 7.8). Fractions containing the pure protein
were concentrated using Amicon Centrifugal Filters, aliquoted, and stored at -80° C. The gene
coding for NTD was overexpressed and the protein was purified in the same manner as described
above for the BD, except the plasmid, pAEP5, was used in place of pEMP3.
3.2.6 Purification of Biotin Carboxylase, Carboxyltransferase and Biotin Carboxyl Carrier
Protein
Biotin carboxylase with a His-tag on the N-terminus was purified according to Blanchard
et al. [10]. Carboxyltransferase with a His-tag on the N-terminus of the α-subunit was purified
according to Blanchard & Waldrop [11]. BCCP with a His-tag on the N-terminus was purified
according to Evans et al. [12].
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3.2.7 Purification of 1,3,6,8-Tetrahydroxynapthalene Synthase (THNS).
The plasmid pAER1 was transformed into E. coli BL21 (DE3) cells. An overnight of this
strain was used to inoculate 0.5 L LB medium in a 2 L beveled flask, which contained 50 µg
streptomycin. Cultures were incubated at 37° C until an OD600 of 0.6. The cultures were cooled
to room temperature and expression induced using 250 µM IPTG. The cultures were incubated
with shaking for an additional 3-5 hours. The cells were pelleted, and then frozen at -20° C. The
cell pellets were suspended in buffer (20 mM NaH2PO4, 500 mM NaCl, and 15 mM imidazole
(pH 7.8)), then lysed by sonication and passage through a French press. DNase was used to
remove nucleic acids. The cell lysate was centrifuged at 17,096g for 60 min at 4° C. The
supernatant was loaded onto a nickel affinity column that had been washed with 10 column
volumes of buffer (20 mM NaH2PO4, 500 mM NaCl, and 15 mM imidazole (pH 7.8)). Protein
was eluted into 5 mL fractions using a segmented gradient starting with 8 column volumes of
0−10% elution buffer (20 mM NaH2PO4, 500 mM NaCl, and 250 mM imidazole (pH 7.8)), then
by 12 column volumes of 10−100% elution buffer, and lastly, 8 column volumes of 100%
elution buffer.
Fractions containing THNS were concentrated using Amicon Centrifugal Filters and
purified over a size exclusion column in a buffer containing 10 mM HEPES and 150 mM KCl
(pH 7.8). Fractions containing the pure protein were concentrated using Amicon Centrifugal
Filters, aliquoted, and stored at -80° C.
3.2.8 In vivo Purification of the Acetyl-CoA Carboxylase Complex in the Absence of the Nterminal Domain of Biotin Carboxyl Carrier Protein
The plasmid coding for the BD (pEMP3) was transformed into E. coli BL21 (DE3). An
overnight of that strain was then used to inoculate 1 L LB medium in a 2 L beveled flask, which
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contained 100 µg kanamycin. Cultures were incubated at 37° C until saturated. The cultures were
cooled to room temperature and expression induced using 500 µM of IPTG. The cultures were
incubated with shaking overnight. The cells were pelleted and then frozen at -20° C.
The cell pellets were thawed and resuspended in buffer (20 mM NaH2PO4, 500 mM
NaCl, and 15 mM imidazole (pH 7.8)), then sonicated and passed through a French press to lyse
the cells. DNase was used to remove nucleic acids and the cell lysate was centrifuged at 17,096g
for 60 min at 4° C, and the pellets were discarded. The supernatant was loaded onto a nickel
affinity column that had been washed with 10 column volumes of buffer (20 mM NaH2PO4, 500
mM NaCl, and 15 mM imidazole (pH 7.8)). Protein was eluted into 5 mL fractions using a
segmented gradient starting with 8 column volumes of 0−10% elution buffer (20 mM NaH2PO4,
500 mM NaCl, and 250 mM imidazole (pH 7.8)), then by 12 column volumes of 10−100%
elution buffer, and finally by 8 column volumes of 100% elution buffer. Fractions containing the
complex were pooled and concentrated using dialysis tubing with a MWCO of 3K kDa and
allowed to dehydrate in polyvinylpyrrolidone. Fractions containing the pure complex were run
on a 15% SDS-PAGE gel.
3.2.9 Pull-Down Assays Targeting the N-terminal Domain of Biotin Carboxyl Carrier Protein
and Full-Length Biotin Carboxyl Carrier Protein
Pull downs targeting NTD or the full-length BCCP utilized biotin agarose resin. The
resin (500 µl) was aliquoted into a 1.5 mL micro centrifuge tube, and pelleted at 14,549g. The
supernatant was removed, and the resin was rinsed with 0.5 ml PBS (pH 7.4). This process was
repeated twice. The resin was then resuspended in 50 µl of a solution (10 mM HEPES (pH 7.8)
and 150 mM KCl) containing 10.4 µM NTD, or 20 µM full-length BCCP. The suspension was
then incubated on a rotary incubator for two hours at room temperature. The resin was then
pelleted at 14,549g. and the supernatant removed. The resin was washed 3 times, resuspended in
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30 µl of 25 mM biotin (pH 7.9) and incubated on a rotary shaker for 2 hours at 37° C. The
supernatant was run on a 15% SDS-PAGE gel.
3.2.10 Steady-State Kinetic Assays
The activity of biotin carboxylase [10], acetyl-CoA carboxylase complex [2], ACC
complex lacking the NTD, and the reconstituted ACC complex (which contains BD and NTD
purified separately and then combined) were all determined by following the production of ADP
using a coupled enzyme assay with pyruvate kinase and lactate dehydrogenase as previously
described [2, 10]. The activity of carboxyltransferase was determined using a coupled enzyme
assay as previously described [11]. Initial velocities were measured using a Cary 60 (Agilent)
spectrophotometer interfaced with a personal computer with a data acquisition program.
Velocities were reported as µmol of product per minute per milligram of the non-varied protein.
3.2.11 Measurement of Malonyl-CoA Production using THNS
To determine malonyl-CoA production in the presence and absence of the N-terminal
domain the following components were mixed: 8 µM BC, 6 µM CT, 1 mM acetyl-CoA, 0.4 mM
ATP, 37.1 µM of THNS, and 50 µM of either full-length BCCP, the BD, or reconstituted BCCP
(the BD and NTD combined) in 10 mM HEPES (pH 7.8) and 150 mM KCl. It is important to
note the enzyme THNS catalyzes the cyclization of malonyl-CoA to form
tetrahydroxynapthalene, or THN. Under oxidizing conditions, THN spontaneously converts into
flaviolin, which absorbs at 340 nm. It has been shown that THN converts to flaviolin over a 6hour period [13]. Thus, the absorbance of the mixture was measured at 340 nm upon addition of
THNS, and again after 6 hours. All experiments were done in triplicate.
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3.2.12 Determining Malonyl-CoA Production in a Single Turnover of Acetyl-CoA Carboxylase
Invitrogen His-Tag Dynabeads (180µl) were washed 3 times with PBS (pH 7.4) and then
resuspended in a 100 µL solution of BC (47.6 µM) and a solution of either 100 µL of BCCP (56
µM), or 150 µL BD (125 µM), or reconstituted BCCP (150 µM BD and 25 µL of NTD (240
µM)). The proteins were allowed to attach to the beads for 30 minutes on a rotary shaker at room
temperature, then 0.4 mM ATP was added and the suspension incubated on a rotary shaker for
10 minutes at room temperature. The beads were then separated out of solution with a
neodymium magnet and washed with PBS (pH 7.4) three times. The beads were suspended in 50
µL of CT (10 µM) and 200 µL acetyl-CoA (20 mM) and allowed to incubate on a rotary shaker
for 10 min at room temperature. The beads were next separated out of solution using a
neodymium magnet, and the supernatant transferred to a 1 cm path length quartz cuvette. Finally,
200 µL of THNS (37.1 µM) was added, the reaction mixed and incubated for 10 min. at which
point the absorbance at 340 nm was measured. After a 6-hour incubation [13], the absorbance at
340 nm was measured again. All experiments were done in triplicate.
3.2.13 Kinetic Analysis
Data were analyzed by nonlinear regression using the computer programs of Cleland
[14]. Data describing competitive inhibition were fitted to equation 1 where v is the initial
velocity, V is the maximal velocity, A is the substrate concentration, Km is the Michaelis
constant, I is the concentration of the inhibitor and Ki is the inhibition constant.
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3.2.14 Secondary Structure and Disorder Prediction
Secondary structure prediction was conducted with PSIPRED 4.0 [15]. Four different
methods have been used to predict disordered regions in BCCP, DISOPRED3 [16], IUPred [17],
disEMBL 1.5 [18], and prDOS [19].
3.3 Results
3.3.1 The Role of the N-terminal Domain (NTD) in Complex Formation.
Previous studies have shown that bacterial ACC forms a complex of the subunits BC, CT,
and BCCP [2]. To determine if the NTD plays a role in the formation of the ACC complex, NTD
was deleted, and the gene for isolated BD with a His-tag on the N-terminus was overexpressed
extragenomically. If the NTD is not required for complex formation, then when the BD is
purified by nickel-affinity chromatography it will pull-down the endogenous BC and CT
subunits. As shown in Figure 3.1, Lane 1, BC, CT, and the BD are present indicating formation
of the macromolecular complex. It is interesting to note there is also a faint band representing
full-length BCCP. This is most likely due to the fact that the complex requires more than one
BCCP protein to form [20], thus endogenously expressed BCCP was also incorporated into the
macromolecular complex. These results suggest NTD is not required for ACC complex
formation.
3.3.2 The Effect of NTD on Enzymatic Activity
As NTD is not required for the formation of the macromolecular complex of ACC, the
role of NTD must be catalytic. The effect of the NTD on the half-reactions (Scheme 3.1)
catalyzed by the isolated subunits, BC (reaction 1) and CT (reaction 2) was examined first.
Figure 3.2 A shows the effect of the NTD on the reaction catalyzed by BC. It is important to
note isolated BC exhibits a slow bicarbonate-dependent ATPase reaction in the absence of biotin
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[10]. Thus, the ATPase activity of BC in the absence of biotin was measured and set to 100%
(Figure 3.2 A, Black). When measuring the activity of BC in the presence of BCCP, the ATPase
activity was zero (Figure 3.2 A, Stripes), consistent with previous studies [2]. In contrast, the
BD increased the ATPase activity 182% (Figure 3.2 A, Dots) compared to BC alone, which is
also consistent with previous studies [9]. When the two domains of BCCP are combined
(heretofore referred to as reconstituted BCCP), the activity is only 9% higher relative to BC
alone (Figure 3.2 A, Squares). In other words, when BD and NTD were combined, the negative
effect on catalysis was similar to that of full-length BCCP. These results indicate that NTD
modulates the activity of the BC subunit.

Lane 1

BC

Lane 2

50 kDa
37 kDa

CT

α
β

25 kDa
BCCP
20 kDa
BD

15 kDa

Figure 3.1. Formation of the Macromolecular Complex of ACC sans NTD in vivo. Lane 1,
Overexpression of the biotinyl domain bound to BC and CT. Lane 2, Molecular weight markers.
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The effect of NTD on the reaction catalyzed by CT is shown in Figure 3.2 B. The CT
half-reaction is run in the non-physiological direction where malonyl-CoA reacts with the biotin
analog biocytin1 to form acetyl-CoA, and has no activity in the absence of biocytin (Figure 3.2
B, Black) [11]. In the presence of full-length BCCP (Figure 3.2 B, Stripes), there is also no
activity, indicating that BCCP cannot be used as a substrate, which is consistent with previous
reports [2]. In contrast, when BD is used as a substrate (Figure 3.2 B, Dots), the activity
increases dramatically, consistent with previous findings [9]. When reconstituted BCCP is used
as a substrate (Figure 3.2 B Squares), the activity is zero. Thus, just like with the BC subunit,
when BCCP was reconstituted the effect on catalysis is similar to the effect of full-length BCCP.
Therefore, the data from Figure 3.2 demonstrate that NTD acts as a negative regulator of both
half-reactions.
The effect of NTD on the overall reaction catalyzed by ACC (Scheme 3.1) is shown in
Figure 3.3. For the assays in Figure 3.3, the activity of ACC is determined by measuring the
production of ADP from the hydrolysis of ATP in the first half-reaction. In Figure 3.3 (Black),
the activity of ACC using full-length BCCP was measured and set to 100%. When the activity
of the overall reaction was measured using BD instead of full-length BCCP, there was an 87%
decrease in activity (Figure 3.3, Stripes). When NTD was added (i.e. reconstituted BCCP)
activity was restored (Figure 3.3, Dots). Thus, in contrast to the negative effect on the isolated
half-reactions, NTD appears to have a positive effect in the overall reaction catalyzed by ACC.

1

Biocytin is biotin with lysine attached to the valeric acid side chain. Biocytin is used in lieu of
biotin because the Vmax is 3 fold higher compared to using biotin as a substrate [11]
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Figure 3.2. The Effect of NTD on the Enzymatic Activity of the Half-Reactions. A. Effect of
NTD on the half-reaction catalyzed by BC. All reactions were run with 8 µM BC in 10 mM
HEPES (pH 7.8) 150 mM KCl and 0.4 mM ATP. From left to right, the first reaction ( )
represents the ATPase activity of BC. This was used as a control and set to 100%. The second
reaction represents ATPase activity of BC in the presence of 50 µM full-length BCCP. The third
reaction ( ) represents the ATPase activity of BC in the presence of 50 µM BD. The fourth
reaction ( ) represents ATPase activity of BC in the presence of reconstituted BCCP (50 µM of
the BD and 50 µM of NTD). B. Effect of NTD on the half-reaction catalyzed by CT. All
reactions were run with 6 µM CT in 10 mM HEPES (pH 7.8) and 150 mM KCl and 0.15 mM
malonyl-CoA. From left to right, the first reaction represents the activity of CT in the absence of
NTD. The second reaction represents the activity of CT in the presence of 50 µM full-length
BCCP. The third reaction ( ) represents the activity of CT in the presence of 50 µM BD. The
fourth reaction represents the activity of CT in the presence of reconstituted BCCP (50 µM of the
BD and 50 µM of NTD). A (+) symbol below the bar indicates the presence of either BCCP,
BD, NTD or a combination of the aforementioned proteins. Each measurement represents the
average of three replicates ± the standard deviation.
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Figure 3.3. Effect of NTD on the Hydrolysis of ATP in the Overall ACC Reaction. All reactions
contained 8 µM BC, 6 µM CT, in 10 mM HEPES (pH 7.8) and 150 mM KCl, 0.4mM ATP, and
0.15 mM acetyl-CoA. From left to right, the first reaction ( ) represents the activity of ACC in
the presence of 50 µM full-length BCCP. This was used as a control and set to 100%. The
second reaction ( ) represents the activity of ACC in the presence of 50 µM BD. The third
reaction ( ) represents the activity of ACC in the presence of reconstituted BCCP (50 µM of the
BD and 50 µM of NTD). A (+) symbol below the bar indicates the presence of either BCCP,
BD, NTD or a combination of the aforementioned proteins. Each measurement represents the
average of three replicates ± the standard deviation.
To investigate the effect of the NTD on not just ATP hydrolysis (Figure 3.3) but on the
overall reaction, the production of malonyl-CoA was examined. The enzyme 1,3,6,9
tetrahydroxynapthalene synthase (THNS) was utilized to measure malonyl-CoA production by
ACC. THNS catalyzes the cyclization of malonyl-CoA to form tetrahydroxynapthalene. Under
oxidizing conditions, tetrahydroxynapthalene is converted to flaviolin, which absorbs at 340 nm
[13]. The production of malonyl-CoA by ACC using full-length BCCP was set to 100% (Figure
3.4, Black). When the BD was substituted for full-length BCCP there was a 45% decrease in
malonyl-CoA production (Figure 3.4, Stripes). In contrast, when reconstituted BCCP was used,
the same amount of malonyl-CoA was produced compared to full-length BCCP, indicating that
BCCP activity can be reconstituted (Figure 3.4, Dots). It is important to note that the values in
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Figure 3.3 are based on initial velocities, whereas the values in Figure 3.4 are based on a change
in absorbance over a 6 hour incubation period, meaning, the two assays can only be compared
qualitatively. Thus, the results from Figure 3.4 are consistent with the results from Figure 3.3,
and indicate that NTD markedly increases the effectiveness of the overall ACC reaction.
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Figure 3.4. Effect of NTD on the Production of Malonyl-CoA. All reactions contained BC, CT,
ATP, and acetyl-CoA. From left to right, the first reaction ( ) represents the activity of ACC in
the presence of full-length BCCP. This was used as a control and set to 100%. The second
reaction ( ) represents the activity of ACC in the presence of BD. The third reaction ( )
represents the activity of ACC in the presence of reconstituted BCCP. A (+) symbol below the
bar indicates the presence of either BCCP, BD, NTD or a combination of the aforementioned
proteins. Each measurement represents the average of three replicates ± the standard deviation.
3.3.3 The Effect of NTD on Half-Reaction Kinetics
The results from Figure 3.2 show BCCP inhibits activity of both half-reactions of ACC,
whereas BD acts as a substrate. This indicates NTD is the regulatory moiety of bacterial BCCP.
Therefore, the mechanism by which NTD inhibits BC and CT activity was investigated using
dead-end inhibition analyses. A competitive inhibition pattern was observed when biotin, a
substrate for BC, was varied at fixed increasing concentrations of NTD (Figure 3.5 A). When
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data were fitted to equation 1, an inhibition constant (Ki) of 204.0 ± 31.0 µM was determined.
Consistent with the BC half-reaction, NTD also exhibited a competitive pattern versus biocytin,
when assaying CT (Figure 3.5 B). When data were fitted to equation 1 an inhibition constant (Ki)
of 119.8 ± 13.9 µM was calculated. A competitive inhibition pattern usually indicates the
inhibitor is binding in place of the substrate in the active site. If NTD bound in the active site of
either BC or CT, then it would act as an inhibitor in the overall reaction, thereby preventing
production of malonyl-CoA. The data from Figure 3.3 and Figure 3.4 refute this conclusion, so it
is unlikely NTD is binding in the biotin site of either BC or CT. A possible explanation for the
competitive inhibition patterns observed in Figure 3.5 is that NTD binds the substrate
biotin/biocytin, and inhibits activity by substrate depletion.
To determine if NTD binds biotin, biotin linked agarose beads were used as a target to
immobilize purified NTD. After washing to remove any excess NTD, the beads were incubated
with free biotin to act as a competitor with the biotin attached to the agarose beads. As seen in
Figure 3.6 A, NTD is present in the eluent, indicating that it does bind biotin. When full-length
BCCP was used in place of NTD a similar result was observed (Figure 3.6 B), indicating BCCP
also binds biotin. The discovery that the N-terminal domain of BCCP binds biotin explains the
observation by Choi-Rhee and Cronan [21], that overexpression of the gene coding for NTD
extragenomically is toxic, because the NTD binding biotin decreases the availability of the
vitamin. This would prevent biotin protein ligase from biotinylating ACC, thereby decreasing
activity of ACC, and by inference cell growth.
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Figure 3.5. Inhibition of the Half-Reactions by NTD. A. Inhibition of the BC half-reaction by
NTD. All reactions contained 8 µM BC in 10 mM HEPES (pH 7.8) and 150 mM KCl. Inhibition
by NTD on the BC half-reaction at 0 µM (l), 50 µM (n), and 100 µM (u) while varying biotin
and holding ATP constant at 0.4 mM. The points represent observed velocities, while the lines
represent best fit of the data to equation 1. B. Inhibition of the CT half-reaction by NTD. All
reactions contained 6 µM CT in 10 mM HEPES (pH 7.8) and 150 mM KCl. Inhibition by NTD
on the CT half-reaction at 0 µM (l), 50 µM (n), and 100 µM (u) while varying biocytin and
holding malonyl-CoA constant at 0.15 mM. The points represent observed velocities, while the
lines represent best fit of the data to equation 1.
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A.

B.

BCCP
NTD

Figure 3.6. Pull-Down Assays to Determine if NTD and BCCP Bind Biotin. A. Represents
biotin agarose beads bound to NTD. B. Represents biotin agarose beads bound to BCCP.
The pull-down assays support the notion that the inhibition patterns in Figure 3.5 are due
to NTD binding biotin, inhibiting the reaction by substrate depletion. Traditionally, enzyme
inhibition by substrate depletion results in non-linear double-reciprocal plots, however, this only
occurs when the substrate and inhibitor concentrations are of comparable magnitudes [22]. In
Figure 3.5 the concentration of biotin is mM, while the concentration of NTD is µM, resulting in
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insignificant depletion of the substrate biotin, which gives a pure competitive inhibition pattern
[22].
There are two possible mechanisms for enzyme inhibition by substrate depletion. One
mechanism involves the inhibitor (I) binding the substrate (S) (Scheme 3.2).

Scheme 3.2.
An alternative mechanism occurs when the inhibitor (I) binds the substrate (S) and the inhibitorsubstrate complex (SI) binds to the enzyme (E) competing with free substrate (S) (Scheme 3.3)
[22].

Scheme 3.3.
When the activity of the overall reaction is measured where NTD is varied and the
complex composed of BC, the BD, and CT was held constant, the Km for NTD was 2.85 ± 0.03
µM. This is 72-fold and 42-fold lower than the inhibition constants (Ki) for NTD in the halfreactions catalyzed by BC or CT, respectively. If the mechanism of inhibition by NTD for the
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half-reactions occurred as in Scheme 3.3 where the NTD-inhibitor complex binds to either BC or
CT, the inhibition constant would be expected to be closer to the Km for NTD binding. The fact
that the inhibition constants for BC and CT are significantly higher than the Km for NTD binding
suggests the mechanism of inhibition is Scheme 3.2.
3.3.4 The Role of NTD in the Catalytic Mechanism
One possible physiological role for NTD is to stabilize the carboxybiotin intermediate
during translocation from BC to CT. To test this postulate, the BC-BCCP complex was formed
in vitro and bound to His-tag Dynabeads via a His-tag on their N-termini. The substrate ATP
was added and the first half-reaction, in which carboxybiotin is formed (Scheme 3.1), was
allowed to proceed for 10 min. The beads were pelleted and washed to remove any unreacted
ATP. If the N-terminus protects carboxybiotin, the mixture should contain BC, BCCP, and
carboxybiotin, which interacts with the N-terminal domain of BCCP. To transfer the carboxyl
group from carboxybiotin to acetyl-CoA to form malonyl-CoA, CT and acetyl-CoA were added.
The amount of malonyl-CoA produced was determined using THNS, which converts malonylCoA into tetrahydroxynapthalene, which under oxidizing conditions forms flaviolin [13]. The
results are shown in Figure 3.7. The amount of malonyl-CoA formed using full-length BCCP
was set to 100% (Figure 3.7, Black). To evaluate if the NTD stabilizes carboxybiotin, the
experiment was repeated using BD in place of BCCP. If the NTD does stabilize the
carboxybiotin, there should be no production of malonyl-CoA in its absence, as the
carboxybiotin would be quickly decarboxylated. When the BD was used as the source of biotin
the percent activity was 16% compared to full-length BCCP (Figure 3.7, Stripes). Though some
flaviolin, and by inference malonyl-CoA was produced, this small amount may be attributed to a
small amount of carboxybiotin remaining after the first step of the experiment. Lastly, when
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reconstituted BCCP was used, malonyl-CoA production was 78% compared to full-length BCCP
(Figure 3.7, Dots), which indicates that the two domains of BCCP do not need to be covalently
linked in order to catalyze the reaction. Thus, the results suggest that in the absence of NTD, the
carboxybiotin intermediate readily decomposes, and the role of NTD is to stabilize the
carboxybiotin intermediate.
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Figure 3.7. The Effect of NTD on the Stabilization of the Carboxybiotin Intermediate. All
reactions contained BC, CT, ATP, and acetyl-CoA. From left to right, the first reaction ( )
represents malonyl-CoA production using full-length BCCP. This was used as a control and set
to 100%. The second reaction ( ) represents malonyl-CoA production using BD in place of
full-length BCCP. The third reaction ( ) represents malonyl-CoA production using
reconstituted BCCP in place of full-length BCCP. A (+) symbol below the bar indicates the
presence of either BCCP, BD, NTD or a combination of the aforementioned proteins. Each
measurement represents the average of three replicates ± the standard deviation.
3.4 Discussion
3.4.1 The NTD is Unique to Bacterial Acetyl-CoA Carboxylase
Most bacterial BCCP contains a domain that is homologous to NTD from E. coli,
however, this domain does not exist in eukaryotic ACC. The three-dimensional structure of
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ACC from yeast gives insight into why the eukaryotic enzyme does not require a domain
homologous to NTD. ACC from yeast is a homodimer, where each subunit has domains
corresponding to the BC and CT proteins found in E. coli, and a domain homologous to the BD
domain in E. coli BCCP [23]. The three-dimensional structure from yeast contains a channel
through which the BCCP domain, containing carboxybiotin, translocates during catalysis. This
channel is most likely responsible for protecting the carboxybiotin intermediate, thus, eukaryotic
ACC would not require a domain homologous to NTD. This begs the question of why the NTD
in bacterial ACC was conserved throughout evolution.
3.4.2 The NTD in Bacterial ACC Stabilizes the Carboxybiotin Intermediate.
Any proposed function for NTD in bacterial ACC begins with the observation that fulllength BCCP prevents ATP-hydrolysis by isolated BC [2], whereas the BD can be used as a
substrate for isolated BC [9]. Therefore, in the absence of NTD, the carboxybiotin covalently
linked to the BD must be undergoing nonproductive decarboxylation after each reaction with
isolated BC to allow for multiple turnovers. This observation combined with the findings in this
study suggest the mechanism by which NTD inhibits ATP hydrolysis in the isolated BC reaction
is by binding and stabilizing the carboxybiotin, which prevents nonproductive decarboxylation
and removes biotin as a substrate thereby preventing multiple turnovers. Ultimately, the NTD
acts as a regulatory moiety of BCCP to prevent ATP hydrolysis by isolated BC. This fact is
important physiologically because it prevents wasteful hydrolysis of ATP by the BC-BCCP
complex when the CT subunit and its substrate acetyl-CoA are not available.
Protection of the carboxybiotin intermediate has also been observed in the related biotindependent enzyme pyruvate carboxylase [24, 25, 26]. Pyruvate carboxylase has BC and BCCP
functions similar to ACC as well as a pyruvate carboxylation site that mimics the CT subunit in
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ACC. These proteins for pyruvate carboxylase form domains on a single polypeptide. Pyruvate
carboxylase catalyzes the carboxylation of pyruvate to form oxaloacetate where the allosteric
activator acetyl-CoA is essential for activity. As with ACC, the biotin carboxylase and pyruvate
carboxylation domains communicate. In the case of pyruvate carboxylase, the communication is
mediated via acetyl-CoA. In the absence of acetyl-CoA, the BCCP domain has unrestricted
movement, which allows the carboxybiotin moiety to be readily decarboxylated by either the
biotin carboxylase domain or an empty pyruvate carboxylation active site. In contrast, acetylCoA restricts the BCCP domain movement thereby protecting the carboxybiotin intermediate. In
an analogous manner, the NTD of ACC performs the same function.
3.4.3 The N-terminal Domain of Biotin Carboxyl Carrier Protein is Flexible
If the role of NTD is to inhibit decarboxylation of the carboxybiotin intermediate, then
the domain is likely to exhibit a modicum of flexibility in order to be able to translocate between
BC and CT. The first evidence of the flexibility of NTD came from the crystal structure of fulllength BCCP in complex with BC [20]. In this structure, it was found the BD interacted with BC,
which is consistent with the fact that BD contains the biotin moiety (substrate). There was,
however, no electron density observed for the N-terminal domain, suggesting the domain is
highly flexible [20].
There is no structural data available for the NTD, despite its small size (8.08 kDa).
Therefore, BCCP was modeled computationally to gain insight into the three-dimensional
structure of the N-terminal domain. The secondary structure prediction for the BCCP sequence
was carried out with PSIPRED [15]. The results are shown in Figure 3.8 A. The vertical axis
indicates the probability, from 0 to 1.0, of the formation of either an α-helix (purple) or a β-sheet
(yellow), while the horizontal axis corresponds to the residue number in BCCP. The results

99

indicate residues 3 through 16 form an a-helix, and residues 20-25 and 28-33 form a b-hairpin.
Additionally, Figure 3.8 A reveals a lack of secondary structural elements in the region between
residues 35 and 75. The biotinyl domain starting at residue 79 is composed predominantly of bsheets as predicted by PSIPRED. This is consistent with three-dimensional structures of the
biotinyl domain [27, 28, 29].
In order to further support the secondary structure predictions, the probability of disorder
in the BCCP sequence was predicted using four different programs (Figure 3.8 B). The vertical
axis indicates the probability, from 0 to 1.0, of a region being disordered. All four programs
consistently assign a high disorder probability to residues 35 through 75, whereas the biotinyl
domain is clearly structured. Furthermore, the region of the NTD predicted to form an a-helix
and a b-hairpin also has a relatively low consensus probability of being disordered, which is in
agreement with Figure 3.8 A. Thus, both Figure 3.8 A and B indicate that the N-terminal
domain of BCCP contains a disordered region.
Proteins that contain extensive disordered regions are referred to as intrinsically
disordered proteins or IDPs [30]. An IDP is a protein that lacks a stable three-dimensional
structure and can vary from being completely without structure, to merely having intrinsically
disordered regions [30]. Even if an IDP has some ordered regions, these types of proteins are
extremely difficult to determine three-dimensional structures as they tend to aggregate at high
concentrations, as is the case for NTD [31].
Intrinsically disordered proteins can serve several purposes. Protein regions that lack
stable three-dimensional structures have the ability to interact with multiple partners, because of
the malleability of the region. This explains why the NTD of BCCP can interact with both the
BC and CT subunit of ACC, despite the fact that the three-dimensional structures of BC and CT
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are significantly different [4, 5, 6, 7]. Moreover, intrinsically disordered proteins can aid in the
transport and binding of small molecules, which is consistent with the hypothesis that the NTD
stabilizes carboxybiotin.

Figure 3.8. Prediction of Structural Attributes for BCCP. A. The probability of secondary
structural elements, a-helix and b-strand, estimated by PSIPRED. B. Disorder probability
reported by DISOPRED, IUPred, disEMBL, and prDOS.
3.5 Conclusions
There are three significant findings from this report. First, NTD is not required for
macromolecular complex formation, indicating its major role is catalytic. Second, NTD binds the
biotin cofactor. Third, NTD stabilizes the carboxybiotin intermediate during catalysis.
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CHAPTER 4. CONCLUSIONS
4.1 Conclusions and Future Directions
Acetyl-CoA carboxylase (ACC) is integral to the growth of the cell and therefore a highly
regulated enzyme [1, 2]. The purpose of this dissertation is to describe two distinct mechanisms
of regulation of bacterial ACC: feedback inhibition by palmitoyl-acyl carrier protein (PACP),
and the regulation of catalysis of bacterial ACC by the N-terminal domain of biotin carboxyl
carrier protein (BCCP).
The inhibition of ACC by the downstream product of fatty acid synthesis, PACP, has
been reported [3], though the mechanism was not determined. The work in this dissertation
revealed that PACP inhibits ACC in a hysteretic manner. Physiologically, the hysteresis
exhibited by ACC acts a “surge protector” to mitigate inhibition of the enzyme when the
concentration of PACP rapidly fluctuates. Alternatively, if PACP remains at a high concentration
for a prolonged period of time, ACC activity is inhibited, thereby decreasing production of fatty
acids. PACP was shown to bind to the ACC complex allosterically; however, the exact location
of binding remains unknown. To determine the binding site, a three-dimensional structure of
ACC bound to PACP must be determined.
One of the most significant findings from this study was the discovery that pantothenic
acid is the inhibitory moiety of PACP. Though pantothenic acid derivatives are known to have
anti-malarial activity against Plasmodium falciparum [4] and antibacterial activity against both
Gram-negative and Gram-positive organisms [5, 6, 7], this is the first report of pantothenic acid
inhibiting ACC in E. coli. Furthermore, pantothenic acid was shown to inhibit ACC in a timedependent manner, and inhibit allosterically, indicating it is binding in a similar location to
PACP. Thus, pantothenic acid could be used as a scaffold to develop novel antibacterial agents
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against ACC. Again, for this to occur the three-dimensional structure of ACC in the presence of
pantothenic acid must be determined.
The regulation of ACC by the N-terminal domain in bacterial BCCP is well documented;
however, the mechanism by which it regulates ACC catalysis had yet to be discovered [8, 9].
The work in this dissertation suggests the N-terminal domain is not required for complex
formation, thus the role of this domain is catalytic. It was also determined that the N-terminal
domain stabilizes the carboxybiotin intermediate, thereby protecting it during, and possibly
aiding in, translocation from BC to CT. The stabilization of the carboxybiotin intermediate by
the N-terminal domain of BCCP explains the absence of the N-terminal domain in eukaryotes,
e.g. the fact that the structure of ACC in yeast contains a channel, which most likely protects the
carboxybiotin moiety, rendering a separate N-terminal domain of BCCP obsolete [10].
Computational modeling indicates the N-terminal domain is disordered, and therefore
highly flexible. Intrinsically disordered proteins, such as the N-terminal domain, are capable of
being involved in a variety of regulatory roles, as these domains are malleable. This explains
why the N-terminal domain can be involved in regulating both transcription of the accBC operon
and catalysis by ACC, [8, 9, 11]. The highly flexible nature of N-terminal does not lend itself to
structural studies; however, the evidence in this study indicates that the N-terminal domain may
stabilize upon substrates binding to BC. To validate this hypothesis a three-dimensional structure
of the BC-BCCP complex in the presence of the carboxybiotin analog N1'-methoxycarbonyl
biotin methyl ester and the product ADP must be determined [12].
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